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HEPARIN PHARMACOKINETICS AND PHARMACODYNAMICS
IN THE RABBIT: FACTORS INFLUENCING
BIOAVAILABILITY AND CLEARANCE
Dr Lynn M. Manson
ABSTRACT
Unfractionated heparin has been the preferred anticoagulant for the prophylaxis and
treatment of a wide range of conditions for over 50 years. Despite being used widely,
its pharmacodynamic and pharmacokinetic characteristics remain poorly understood.
Its clinical use is hindered by its poor bioavailability after subcutaneous injection, and
as its half-life is also relatively short it must be administered therapeutically by
continuous intravenous infusion. There is wide variation in dose response among
patients and so the anticoagulant effect must be monitored closely by laboratory
testing to optimise efficacy. Factors responsible for this variability have not been
identified, but reversible heparin neutralisation by non-specific protein binding and
increased heparin clearance in disease states have been implicated.
These disadvantages are overcome by the low molecular weight heparins. Their
greater bioavailability at low doses and longer half-lives allow them to be administered
to out-patients once or twice daily by subcutaneous injection and their more
predictable anticoagulant response to weight-adjusted doses obviates the need for
laboratory monitoring.
In order to improve our understanding of heparin bioavailability and clearance, and in
an attempt to identify the factors responsible for variation in dose response, a
reproducible in vivo model of heparin pharmacokinetics and pharmacodynamics was
established in the rabbit. This has demonstrated that impaired heparin recovery is
caused by increased non-specific protein binding. The extent of reversible protein
binding is substantially less with low molecular weight than unfractionated heparin,
and in contrast to unfractionated heparin which showed a significant reduction in
recovery in experimental endotoxaemia, low molecular weight heparin does not bind
to proteins that are released in response to endotoxin as its recovery was unaffected
by acute endotoxaemia. The findings suggest that the binding proteins are likely to be
proteins released from activated platelets, endothelial cells or leucocytes. There was
no evidence that increased heparin clearance contributes to the reduced recovery
observed in acute illness.
The novel in vivo application of low affinity heparin caused a significant improvement
in the recovery and half-life of unfractionated heparin, and the clinical implications of
obtaining the benefits of the low molecular weight heparins at a fraction of their cost
by using the combination of low affinity and unfractionated heparins are great.
Although the results in rabbits may differ quantitatively from those in humans, they
are likely to be qualitatively similar, and so it is probable that the variable
anticoagulant response to heparin seen in patients is caused by variation in plasma
protein binding rather than altered heparin clearance.
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ABBREVIATIONS USED IN TEXT
AT III Antithrombin III
AUC Area under the curve
HAH High affinity heparin
HC II Heparin cofactor II
Heparin Unfractionated and low molecular weight heparins
HPLC High performance liquid chromatography
i.v. Intravenous
LAH Low affinity heparin
LMWH Low molecular weight heparin
LPS Lipopolysaccharide
NRS Normal rabbit serum
PF4 Platelet factor 4
PPP Platelet-poor plasma
RES Reticuloendothelial system
SHPP 3-(4-hydroxyphenyl) propionic acid N - hydroxysuccinimide ester
UFH Unfractionated heparin
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In Europe and North America each year, 2-4 percent of the population suffers a
symptomatic thromboembolic event requiring anticoagulant therapy (van Beek, 1996).
The standard management of such patients has for many years involved the in-patient
administration of i.v. UFH for up to 10 days, followed by oral anticoagulant therapy
for at least 3 months (Clark, 1995; Hirsh, 1991). UFH is an effective anticoagulant in
the prevention and treatment of thromboembolic disease, and is also beneficial in the
prevention of mural thrombosis after myocardial infarction, in the treatment of
unstable angina, and in the prevention of coronary artery rethrombosis after
thrombolysis. It is also used to prevent thrombosis in extracorporeal devices in
cardiac surgery and haemodialyis, to treat selected cases of disseminated intravascular
coagulation, and to prevent thrombosis in high-risk pregnancies. However, its clinical
usefulness is limited by factors that determine its pharmacokinetic and
pharmacodynamic characteristics. It has poor bioavailability at low doses, it must be
administered parenterally, its half-life is dose-dependent, and the marked variability in
dose-response makes it mandatory to monitor its anticoagulant effect closely by
laboratoy testing.
There are two potential explanations for the marked variation in anticoagulant
response to UFH. Firstly, non-specific binding of heparin to plasma proteins
neutralises its anticoagulant activity and limits the amount of heparin that is available
to bind to AT III, thereby decreasing its anticoagulant effect. Variations in levels of
plasma proteins could result in variability in anticoagulant response. Secondly, the
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underlying disease process may alter the function of components of the UFH
clearance mechanisms such that UFH clearance may be increased and recovery
reduced in the sick patient.
In recent years, low molecular weight derivatives of UFH have been prepared by a
variety of techniques (Table 1), and have different pharmacokinetic and
pharmacodynamic properties when compared with UFH. LMWHs have better
bioavailability than UFH as they bind less to plasma proteins and they have a more
predictable dose response than UFH. The effect of acute illness on the
pharmacokinetics and pharmacodynamics of the LMWHs is unknown.










Ardeparin Peroxidative depolymerisation 6000 1.9
Dalteparin Nitrous acid depolymerisation 6000 2.7
Enoxaparin Benzylation and alkaline 4200 3.8
depolymerisation
Nadroparin Nitrous acid depolymerisation 4500 3.6
Reviparin Nitrous acid depolymerisation, 4000 3.5
chromatographic purification
Tinzaparin Heparinase digestion 4500 1.9
Although UFH was first discovered over 80 years ago, its pharmacokinetics remain
poorly understood. UFH is cleared predominantly by the saturable, or cellular
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mechanism and although the elimination process was thought to follow first-order
kinetics, the half-life of UFH increases as the dose administered increases. In contrast,
LMWHs are eliminated from the circulation by the renal route. This clearance
mechanism was thought to follow zero-order kinetics but surprisingly the half-life of
the low molecular weight heparins is dose-independent, suggesting a first-order
clearance mechansim. In addition, the half-life of LMWH is longer than that of a
comparable dose of UFH because the clearance of LMWH by the renal route is
slower than the clearance of an equivalent dose of UFH by the saturable route. The
effect of acute illness on the mechanisms of clearance are unknown, and previous
reports of their contributions to variability in anticoagulant response are inconsistent.
To investigate the factors responsible for the variable anticoagulant response to
heparin in acute illness, an in vivo model of heparin pharmacokinetics and
pharmacodynamics in the rabbit was established, and the results gained from its use
are reported in this thesis. The in vivo clearance, recovery and metabolism of UFH
and LMWH were compared, and the effect of acute inflammation on these parameters
was assessed in endotoxin-treated animals. The components of the clearance
mechanisms were identified, and attempts were made to modify factors that determine
the bioavailability and clearance of UFH in order to overcome the characteristics that
limit its clinical usefulness.
In accounting for the experimental results obtained it was thought necessary to
consider the inherent differences in the biochemical and antithrombotic properties of




Commercial UFH is derived from mast cells of porcine intestinal mucosa and bovine
lung and prepared as sodium or calcium salts. There is no evidence that the
pharmacokinetic or biological properties of UFH are altered by its tissue source or the
type of salt preparation. It is a strongly negatively-charged glycosaminoglycan
consisting of chains of alternating uronic acid residues, which can be either D-
glucuronic acid or L-iduronic acid, and D-glucosamine residues. The resulting
polysaccharide chain is highly sulphated, with N-sulphate groups on the glucosamine
residues and O-sulphate groups in various positions on both the uronic acid and
glucosamine residues. Both the distribution of glucuronic acid and iduronic acid units
and the sulphation pattern are variable (but not random) which results in a
considerable structural heterogeneity. Commercial preparations of heparin are
polydisperse, with molecular weights ranging from 3,000 to 30,000 Da (mean 12,000
to 16,000 Da), or 10 to 100 monosaccharide residues per chain.
Biological Activity
The anticoagulant activity of UFH is dependent upon its interaction with the naturally-
occurring anticoagulant AT III, and its ability to accelerate greatly the rate by which
AT III inactivates serine proteinases. The active centre serine of thrombin and other
coagulation enzymes (including activated factors IX, X, XI and XII) is inhibited by an
arginine reactive centre of the AT III molecule. UFH binds to lysine sites on AT III
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and produces a conformational change at the arginine reactive centre whch converts
AT III from a progressive, slow inhibitor to a very rapid inhibitor (Rosenberg and
Bauer, 1994). Thrombin and activated factor X (factor Xa) are the serine proteinases
that are most sensitive to accelerated inactivation by the heparin-AT III complex
(Rosenberg and Bauer, 1994). The inactivation of thrombin by AT III in the presence
of optimal concentrations of heparin is accelerated 2000- to 4000-fold, such that the
half-life of free thrombin is reduced from 35 seconds to less than 1 second in the
presence of heparin. An acceleration of comparable magnitude to that observed with
thrombin has been shown for the reaction of AT III with factor Xa in the presence of
heparin, reducing its half-life significantly from 90 seconds. The inactivation of other
coagulation enzymes is accelerated to a much lesser extent, resulting in less of a
reduction in the already relatively prolonged half-lives of factors IXa, XIa and Xlla of
10-25 minutes in the absence of heparin. Once it has induced the conformational
change, UFH dissociates from the complex and can be reused (Rosenberg and Bauer,
1994).
Commercial UFH contains two fractions with greatly differing affinity for AT III. The
high-affinity fraction, which constitutes about one third of the heparin chains, has
high anticoagulant activity and accounts for about 90% of heparin's anticoagulant
activity. The remaining low-affinity heparin (two-thirds of the chains) has low specific
activity at less than 10% of that of the high-affinity fraction. The high-affinity fraction
contains a unique pentasaccharide sequence containing a critically-positioned
glucosamine residue (Choay et al, 1981; Rosenberg and Lam, 1979; Rosenberg and
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Bauer, 1994; Lindahl et al, 1979; Casu et al, 1981) which is not found on the low-
affinity heparin and which constitutes the specific AT III binding region of the high-
affinity fraction. The heparin binding site of AT III has not yet been conclusively
identified, but evidence exists that two arginine- and lysine-rich segments of the AT
ffi molecule are involved, and these are the amino-terminal region up to about residue
50 (Blackburn et al, 1984; Gettins et al, 1992) and a region comprising approximately
residues 100 to 145 (Peterson et al, 1987b; Smith et al, 1990).
Binding of AT III to heparin is a prerequisite for the ability of the polysaccharide to
accelerate the inactivation of all target proteinases by the inhibitor, but the
acceleration of the inactivation of certain proteinases also requires binding of the
enzyme to heparin in a ternary complex. The inhibiton of thrombin requires that
heparin binds to both AT III and the enzyme, but the inhibition of factor Xa requires
that heparin binds only to AT III (Casu et al, 1981). Heparin molecules with fewer
than 18 saccharide residues are unable to bind to thrombin and AT III simultaneously
and cannot catalyse the inhibition of thrombin. In contrast, smaller heparin fragments
are able to catalyse the inhibition of factor Xa by AT III, so long as they contain the
high-affinity pentasaccharide binding site (Lindahl et al, 1984; Oosta et al, 1981;
Nesheim, 1983).
Pharmacokinetics
The disappearance of heparin from plasma can be investigated either by using
biological assays to monitor the anticoagulant activity of heparin in plasma
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(pharmacodynamics) or by estimating the rate of disappearance of radiolabeled
heparin (pharmacokinetics). The two methods differ in the fraction of heparin
molecules that is measured. Only one-third of the molecules in commercial
preparations of UFH bind AT III with high affinity (Andersson et al, 1976). The
remaining two-thirds of fractions with low affinity to AT III have no anticoagulant
effect in vitro and will not be detected by biological assays which are based upon the
ability of heparin to accelerate the AT Ill-dependent inhibition of factor Xa.
Therefore, the disappearance of the anticoagulant effect of heparin monitors the
behaviour of approximately the one-third of UFH molecules with high affinity for AT
III. The low-affinity fractions are still required for heparin to exert maximal
antithrombotic effect, as fractions with only high affinity to AT III are less
antithrombotic than UFH (Barrowcliffe et al, 1984). The radioactive isotope 125 iodine
will bind to derivatised heparin (Greenwood et al, 1963) and this process is
independent of heparin's affinity for AT III (Dawes and Pepper, 1979). Therefore, the
disappearance of radiolabelled heparin from the vascular compartment assesses the
rate of clearance of all heparin molecules regardless of their affinity for AT III, and is
the 'net' product of the clearance of the different heparin moieties. The antithrombotic
effect of the polydisperse UFH is monitored by the clearance of radiolabelled UFH
from plasma, while the anticoagulant effect of its high-affinity fraction is assessed by
biological assays, the majority of which are based upon AT Ill-dependent inhibition of
factor Xa (Caranobe et al, 1986).
When supratherapeutic doses of UFH are injected intravenously in the rabbit, heparin
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that has anticoagulant activity and is structurally intact is excreted in urine (Piper,
1947). Several hours later, the excreted heparin moieties have become desulphated
and depolymerised (Dawes and Pepper, 1979). In contrast, when therapeutic doses of
UFH are injected , only depolymerised and desulphated moieties are excreted (Piper,
1947; Dawes and Pepper, 1979). Desulphation probably precedes depolymerisation
(Dawes and Pepper, 1979) and is likely to occur in the RES (Dawes and Pepper,
1979; Losito et al, 1977; Teien, 1977; Friedman and Arsenis, 1974; Oh et al, 1973;
Bleiberg et al, 1983). Heparin has also been identified in vascular endothelial cells
after parenteral injection (Hiebert and Jaques, 1976; Mahodoo et al, 1977) and
endothelial cells in culture have been shown to have saturable binding sites for heparin
(Glimelius et al, 1978; Barzu et al, 1985). Heparin is endocytosed by the endothelial
cell (Barzu et al, 1985), and it is likely that the endothelium and/or the vessel wall
contains heparin-metabolising activity (Barzu et al, 1987; Glimelius et al, 1978) and
heparin-degrading activity (Barzu et al, 1987; Dawes and Pepper, 1992) but whether
or not these processes occur in vivo has yet to be determined. After desulphation by
the RES, the heparin metabolite is degraded to low molecular weight saccharides,
possibly in the kidneys (Dawes and Pepper, 1979). A heparin-degrading
endoglycosidase has been identified in rat spleen (Hook et al, 1977) but a similar
enzyme has yet to be identified in human renal tissue. Together, these studies suggest
that clearance of UFH from the intravascular space results from a widespread cellular
mechanism of uptake followed by renal degradation of the released, desulphated
product.
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Initial work suggested that the half-life of UFH was dose-independent as clearance of
the anticoagulant activity of therapeutic doses of i.v. heparin was exponential,
consistent with a clearance mechanism that followed first-order kinetics (Olsson et al,
1963; Bjomsson et al, 1982). It was then observed that the half-life of heparin
increased with the dose administered (Bjomsson and Levy, 1979; Olsson et al, 1963;
Bjomsson et al, 1982; Estes, 1970), and that the pharmacodynamics of a large dose of
UFH are best described by a concave-convex curve (de Swart et al, 1982). When this
complex curve is resolved into its two components, it becomes apparent that UFH is
cleared by a combination of saturable (cellular) and non-saturable (renal) mechanisms.
The relative contributions of these two mechanisms is dependent upon the dose of
UFH administered (Boneu et al, 1987a). At therapeutic doses, heparin is cleared
predominantly by the cellular mechanism and the contribution of the renal mechansim
to its clearance is small. At higher doses, when the cellular mechanism is saturated,
heparin is cleared predominantly by the kidneys. Clearance studies in nephrectomised
rabbits provide further evidence of the dose-dependence of heparin clearance
mechanisms, as binephrectomy in the rabbit does not alter the clearance of low dose
UFH but prolongs the clearance of a higher dose (Caranobe et al, 1985).
i) UFH -endothelial cell interactions
In vitro studies have shown that UFH binds to saturable sites on endothelial cells
(Glimelius et al, 1978; Mahodoo et al, 1977), after which it is internalised and
depolymerised (Mahodoo et al, 1977). The interaction of UFH with endothelial cells
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in vivo results in the displacement of PF4 (Dawes et al, 1987). Endothelial binding
sites for heparin have been characterised on both bovine (Vannucchi et al, 1988) and
human (Barzu et al, 1985) cells, and endothelial uptake of heparin is likely to be a
component of the saturable mechanism of clearance of UFH (de Swart et al, 1982).
The cell receptors are not specific for heparin and also interact with other anionic
polyelectrolytes, the affinity increasing with both charge and molecular weight (van
Rijn et al, 1987). The bound UFH is highly antithrombotic but a large proportion is
slowly endocytosed and metabolised (Vannucchi et al, 1988; Barzu et al, 1985;
Dawes and Pepper, 1992). It is incorporated into the subendothelial matrix where it is
catabolised to low molecular weight oligosaccharides devoid of anticoagulant activity.
Although the small fragments may retain their AT III binding capacity (Barzu et al,
1987), they have no anticoagulant activity as the glycosaminoglycan undergoes
complete desulphation which destroys its biological activity, followed by
depolymerisation of the carbohydrate chain (Dawes and Pepper, 1992). In addition,
heparin interacts with growth factors and affects coagulation, fibrinolysis and cell
growth through endothelial-mediated mechanisms (D'Amore, 1990; Minter et al,
1992), many of which are independent of its anticoagulant activity (Sudhalter et al,
1989).
ii) UFH - RES interactions
Peripheral blood monocytes migrate from the marrow to tissues, spending only a few
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hours in the blood. They continue to proliferate in the tissues where, as macrophages,
their lifespan is measured in months or years. Macrophages have a prediliction for the
liver and spleen. Some are fixed to endothelial structures lining the channels
(sinusoids) of these organs and this fixed phagocytic capacity is called the RES. The
cells of the RES play an important role in the metabolism of UFH (Fabian et al, !978).
After i.v. injection, large amounts of radiolabelled UFH are taken up by the liver but
the greatest concentration of radioactivity is found in the spleen (Dawes and Pepper,
1979). The plasma half-life ofUFH in patients with cirrhosis is significantly prolonged
compared with that of normal individuals and AT III activity is lower in normal
individuals compared to that of cirrhotics, and so it is likely that UFH complexed to
AT III is removed from the circulation by the liver (Teien, 1977). Once bound to
specific receptors on the macrophage cell membrane, (Bleiberg et al, 1983), UFH is
phagocytosed and fully desulphated before being returned to the circulation (Friedman
and Arsenis, 1974; Dawes and Pepper, 1979, Wells and Dawes 1995). A heparin N-
desulphamidase has been identified in various mammalian tissues (Dietrich, 1970)
including rat spleen (Friedman and Arsenis, 1974) but O-desulphating activity has not
yet been described. N- and O-desulphation results in loss of protein binding capacity
and biological activity (Dawes and Pepper, 1979). Hepatectomy in the rat decreases
the amount of desulphated heparin present in the circulation compared with normal
rats (Wells and Dawes 1995). However, even in the absence of a functioning liver,
heparin desulphation does occur and the vascular endothelium has been proposed as a
third site of heparin metabolism (Wells and Dawes, 1995; Dawes and Pepper, 1992).
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As the molecular weight of excreted heparin is much less than that of circulating
oligosaccharides, UFH must undergo degradation prior to excretion (Dawes and
Pepper, 1979). A heparin-degrading endoglycosidase has been isolated from rat
spleen (Hook et al, 1977) but the site of degradation in man remains unknown.
Significant amounts of radiolabelled UFH are associated with the kidney after i.v.
adminstration (Dawes and Pepper, 1979) and it is possible that the kidney is the site
of degradation. When UFH is administered in doses which saturate the cellular
clearance mechanism, significant amounts are cleared by the non-saturable route and
the intact UFH which is excreted is not desulphated. It therefore appears that UFH
must undergo desulphation by the cells of the RES before degradation can occur
(Dawes and Pepper, 1979).
Factors affecting bioavailability
UFH binding and neutralising proteins
In addition to its anticoagulant properties, heparin binds to cells (Barzu et al, 1986;
Blieberg et al, 1983; Sobel and Adelman, 1988), influences cell growth (Clowes and
Karnowsky, 1977) and binds to a large number of proteins (Lane, 1989) as a result of
its strong anionic charge. Although the effect of the specific binding of heparin to AT
III is well-documented (Rosenberg and Bauer, 1994), the physiological significance of
many non-specific heparin-protein interactions is poorly understood. UFH binds to
endogenous plasma proteins (such as histidine-rich glycoprotein, polymeric
vitronectin, and fibronectin), to PF4 (released from activated platelets), and to high-
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molecular weight multimers of vWF (released from platelets and endothelial cells)
(Sobel et al, 1991; de Romeuf and Mazurier, 1993). Binding of UFH to plasma
proteins reduces its anticoagulant activity by direct neutralisation and also by reducing
the amount available to bind to AT III (Young et al, 1992). Most in vitro studies of
protein-UFH interactions have used purified sytems and it is unknown if the in vitro
findings are consistent with the protein-UFH interactions which occur in the in vivo
plasma environment. There is evidence to suggest that in a whole plasma environment
incorporating immobilised heparin, histidine-rich glycoprotein is the only plasma
protein likely to neutralise a significant proportion of the anticoagulant activity of a
therapeutic dose of UFH by direct competition with AT III (Dawes, 1993).
Moreover, the contributions of individual protein-UFH interactions to the
phenomenon of heparin resistance (when vast amounts of heparin are required to
achieve a therapeutic anticogulant effect) are largely unknown (Andersen et al, 1981).
Increased non-specific protein binding to UFH has been described in patients
compared with healthy individuals (Young et al, 1992, 1993b) and it has been
suggested that this difference is the result of increased levels of heparin binding
proteins, some of which are likely to be acute phase reactants. Although the levels of
many plasma glycoproteins increase during the acute phase response, increased
synthesis of hepatic messenger RNA is not maximal until 8 hours after the initiation of
the acute phase response, and increased plasma levels of acute phase proteins of
hepatic origin occur several hours thereafter (Koj, 1974). However, the tendency for
increased heparin requirements in heparin resistant patients is present only a few hours
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after the onset of illness and initiation of the disease process (Young et al, 1992).
Therefore, any plasma glycoprotein implicated in heparin resistance must be present in
increased amounts in plasma within a few hours after the onset of the disease process.
This significantly reduces the likelihood of proteins whose raised plasma levels are
determined by increased de novo synthesis (such as traditional acute phase reactants
of hepatic origin) playing a major role in heparin resistance.
LOW MOLECULARWEIGHT HEPARINS
Biochemical Structure
In recent years, low molecular weight derivatives of commercial UFH have been
prepared that have a mean molecular weight of approximately one-third that of UFH.
Like UFH, LMWHs are glycosaminoglycans comprising chains of alternating residues
of D-glucosamine and uronic acid, either L-iduronic or D-glucuronic acid (Rosenberg
and Bauer, 1994). They are fragments of UFH manufactured by controlled enzymatic
or chemical depolymerisation processes that produce chains with a mean molecular
weight of about 5,000 Da and varying anti-Xa : Ha ratios. (Table 1).
Biological Activity
The LMWHs exert their anticoagulant effect in a manner identical to that of UFH.
They bind to AT III through a unique pentasaccharide binding sequence which
induces a conformational change in AT III and results in acceleration of the inhibition
of serine proteases by the naturally-occurring anticoagulant. However, only 15 to
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25% of LMWH chains contain the randomly distributed unique pentasaccharide
binding sequence, compared with approximately one third of UFH chains. The
principal difference between UFH and the LMWHs is in their relative inhibitory
activity against factor Xa and thrombin (Harenberg, 1990). Less than 50 percent of
LMWH chains are long enough to form the ternary AT III-thrombin-LMWH complex
necessary to thrombin activity (Jordan et al, 1980). Therefore, unlike UFH which has
equivalent activity against factor Xa and thrombin, LMWHs have greater activity
against factor Xa compared with thrombin (Table 1).
Pharmacokinetics
The longer half-life, dose-independent clearance and better bioavailability of the
LMWHs give them a more predictable anticoagulant response than UFH (Handeland
et al, 1990). The plasma half-lives of LMWHs are two to four times as long as that of
UFH. This difference results from the two glycosaminoglycans being cleared from
plasma by different mechanisms. The LMWHs are cleared principally by the renal
route because they have much lower affinity for endothelial cells (Barzu et al, 1984,
1987) and the macrophages of the RES (Bleiberg et al, 1983). The ability of UFH and
LMWHs to bind to endothelial cells and macrophages may be dependent upon
molecular weight and charge (van Rijn et al, 1987), but other criteria, such as cellular
affinity for AT III and characteristics of molecular fractions from other heparins, need
to be examined before structural dependency can be confirmed.
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Factors affecting bioavailability
Recovery of LMWH is greater than that of a comparable dose of UFH, and the
bioavailability of LMWH after subcutaneous and i.v. administration is similar. When a
low dose of LMWH is given subcutaneously, approximately 100 percent of the anti-
factor Xa activity administered is recovered, compared with 30 percent with UFH
(Bara et al, 1985), and the bioavailability after a subcutaneous dose is approximately
90 percent of an equivalent dose administered intravenously (Bratt et al, 1986). In
addition, as the anticoagulant response to a given dose of LMWH is highly correlated
with body weight (Matzsch et al, 1987) LMWH is effective when given in standard
weight-adjusted doses (factor Xa U/kg) and laboratory monitoring is unnecessary.
LMWH binding and neutralisingproteins
Binding of proteins to LMWH differs greatly compared with that of UFH. Normal
plasma is known to contain components which neutralise the anti-factor Xa activity of
UFH but not smaller molecular weight fractions of heparin (Andersson et al, 1979;
Lane, 1989), and this is of pharmacodynamic significance. Binding to plasma proteins
may result in reduced recovery of UFH at low concentrations, variation in the
anticoagulant response to a fixed dose of UFH in patients with thromboembolic
disease (Hirsh et al, 1976) and the laboratory phenomenon of heparin resistance
(Cruickshank et al, 1991). LMWH has lower affinity for histidine-rich glycoprotein
(Lane et al, 1986), fibronectin (Dawes and Pavuk, 1991) and PF4 (Lane et al, 1986)
than UFH, which may explain its superior bioavailability at low doses and the more
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predictable anticoagulant response to high doses of LMWH (Handeland et al, 1990).
As LMWHs have much lower affinity for heparin binding proteins than UFH, their
plasma recovery is practically independent of dose and plasma concentration.
However, non-specific plasma protein binding and neutralisation of LMWH
anticoagulant activity does occur, and vitronectin and histidine-rich glycoprotein have
been identified as important modulators of the anticoagulant activity of LMWHs
(Dawes, 1993).
AIMS OF THE THESIS
It is apparent from the work discussed in this introduction that the understanding of
the processes controlling the anticoagulant response to heparin in patients is less than
complete. The objective of the investigations described in this thesis was to gain
further knowledge of the factors responsible for variability in heparin dose response
and included:
1. establishment of an in vivo healthy animal model for the study of heparin
pharmacokinetics and pharmacodynamics;
2. comparison of the pharmacokinetics, pharmacodynamics, tissue localisation and
metabolism ofUFH and the LMWH enoxaparin;
3. assessment of the effect of endotoxaemic shock on heparin bioavailability and
clearance;
4. identification of the factors that determine the anticoagulant response to heparin;
5. modification of factors identified as influencing heparin recovery in an attempt to
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improve UFH bioavailability.
It was hoped that the results obtained would improve our understanding of the factors
that determine the anticoagulant response to UFH and LMWHs in vivo in order to
facilitate optimal prophylactic and therapeutic anticoagulation in the clinical setting.
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CHAPTER 2
PHARMACOKINETICS AND PHARMACODYNAMICS OF
UNFRACTIONATED AND LOW MOLECULARWEIGHT
HEPARINS IN THE RABBIT
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INTRODUCTION
The disappearance of UFH from the vascular compartment can be assessed either by
biological assays or by measuring the rate of disappearance of radiolabeled UFH.
These two methods assess different characteristics of the heterogeneous commmercial
UFH preparations. Initial biological assays used to measure the anticoagulant effect of
UFH were global coagulation assays such as the whole blood clotting time or
activated partial thromboplastin time, but these have been replaced by factor-specific
assays because endogenous substances in blood contribute to the anticoagulant effect
as assessed by global clotting assays (Godal, 1974). The biological effect of UFH is
generally measured ex vivo using an assay based on anti-factor Xa activity because
providing the AT III pentasaccharide binding sequence is present, the ability of UFH
to accelerate the AT Ill-dependent inactivation of factor Xa is independent of chain
length whereas its capacity to accelerate thrombin inactivation is chain-length
dependent. However, only one-third of the molecules in commercial preparations of
UFH (Andersson et al, 1976) and 15 to 25 percent of molecules in LMWH
preparations contain the unique high-affinity pentasaccharide binding sequence
(Harenberg, 1990). Thus, the anticoagulant clearance curve of UFH reflects the
clearance of the high-affinity fractions only, while the elimination curve of
radiolabelled UFH is a "net" summation of the more complex clearance curves of the
different high- and low-affinity heparin fractions (Caranobe et al, 1986). Fractions
with low affinity for AT III still have clinical significance because although they are
devoid of an anticoagulant effect in vitro, they still have antithrombotic activity as
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high-affinity fractions to AT III have less antithombotic effect than UFH (Holmer et
al, 1982; Thomas et al, 1982; Barrowcliffe et al, 1984; Mattsson et al, 1989). The
mechanism by which LAH enhances the antithrombotic effect of HAH is as yet
unknown. Thus, in order to optimise clinical relevance, models of heparin clearance
must be used which are not based solely on anticoagulant activity in order to give an
accurate impression of clearance of antithrombotic activity.
Early investigations with UFH using global clotting assays suggested that heparin was
cleared by a first-order exponential process (Estes et al, 1969; Olsson et al, 1963;
Perry et al, 1974) as the clotting assay declined in a log-linear fashion. However, later
studies using radiolabelled UFH (Dawes and Pepper 1979) and anti-factor Xa assays
(de Swart et al, 1982) demonstrate that the pharmacokinetics of heparin are far more
complex, as a characteristic concave-convex elimination curve is found (Boneu et al,
1989). The elimination of heparin is preceded by a fast initial removal of anticoagulant
activity suggestive of an equilibration phase resulting from mixing of the drug in
plasma and from distribution to other compartments. The complex concave-convex
elimination curve cannot be explained by a simple kinetic linear model but the
nonlinearity can be explained by an exponential mechanism (which is saturable) and a
linear elimination mechanism (which is non-saturable) operating in parallel. The
contribution of each mechanism to the overall clearance of glycosaminoglycans is
dose- and type-dependent. The half-life of UFH is dose-dependent, increasing as the
dose administered increases. At lower doses, the saturable mechanism is the principal
route of UFH elimination, and this mechansim follows first-order kinetics. At higher
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doses, this elimination mechanism is saturated and UFH is increasingly cleared by the
nonsaturable route which follows zero-order kinetics. When therapeutic doses of
UFH are administered, the zero-order component of clearance appears to be of
minimal clinical significance and a dominant first-order process can be assumed
(Kandrotas et al, 1989). However, the dose-dependent half-life of UFH can be
explained by the change that occurs in the dominant clearance mechanism (from the
rapid saturable to the slower non-saturable route) if the dose needs to be increased to
achieve a therapeutic effect. The components of the saturable mechanism are cellular,
and in vitro evidence suggests that UFH probably binds to endothelial and RES cells
from where it is internalised, desulphated and depolymerised (Hook et al, 1977; Barzu
et al, 1987; Bjornsson et al, 1988; Vannucchi et al, 1988). In contrast, the elimination
of LMWH appears to occur almost solely by a non-saturable mechanism (Boneu et al,
1987b) and cellular binding plays a minimal role in LMWH clearance (Palm and
Mattsson, 1987a). The half-life of LMWH is approximately twice as long as that of
UFH and is not dose-dependent (Boneu et al, 1987b; Bara and Samama, 1988). The
primary route of LMWH elimination appears to be renal (Palm and Mattsson 1987a,
1987b; van Rijn et al, 1987) and high concentrations of LMWH are found in the urine.
The factors controlling this elimination process have yet to be described but it is
unlikely that elimination occurs by passive glomerular filtration, since negatively
charged heparin molecules will be repelled by the negatively charged heparan sulphate
molecules that are abundant in the glomerular basement membrane (Kanwar and
Farquhar, 1979). Further investigations are required to determine the pathophysiology
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of renal glycosaminoglycan clearance.
It has long been known that there is wide variation in the anticoagulant response to a
standard dose of UFH both in healthy volunteers and in hospitalised medical and
surgical patients (Basu et al, 1972; Simon et al, 1978) and the most extreme example
of this variability is exemplified by the laboratory condition of heparin resistance,
when vast amounts of UFH are required to achieve a therapeutic level of
anticoagulation (Cruickshank et al, 1991). There are a number of possible
explanations for the increased heparin requirements seen in a proportion of patients
treated with UFH. Increased UFH clearance in pulmonary embolism compared with
venous thromboembolism may be caused by the disease process (Hirsh et al, 1976),
but although similar findings can be reproduced in experimental pulmonary embolism,
the underlying mechanism remains unclear (Chiu et al, 1977), and there is no evidence
that heparin clearance is increased in cases of venous thromboembolism with
excessive heparin requirements. Further investigation of the endothelial and
reticuloendothelial macrophage mechanisms of UFH clearance is required to
determine the contribution of the clearance mechanism to heparin resistance.
Increased plasma levels of procoagulants (Edson et al, 1967) and reduced
concentrations of AT III (Hirsh, 1986) theoretically could result in increased heparin
requirements in order to achieve a therapeutic level of anticoagulation, but such
abnormalities have not been found widely in clinical practice. There is evidence,
however, that reversible heparin neutralisation (due to heparin binding to other plasma
proteins which compete with AT III for heparin) is a major determinant of the
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anticoagulant response to a fixed dose of UFH (Young et al, 1992). It has been
suggested that variability in dosage requirements results from differences in
concentrations of heparin neutralising proteins among patients, and those with heparin
resistance will have the highest levels of neutralising plasma proteins. The identity of
the neutralising proteins remains to be determined. Traditional acute phase reactants
could play a role but the tendency to higher heparin requirements is present in
patients' plasma very soon after the onset of the disease process even before heparin
is commenced (Young et al, 1992). This does not allow sufficient time for
upregulation of acute phase protein synthesis and release (Koj, 1974). In comparison,
the recovery of LMWH is much less affected by non-specific binding to plasma
proteins (Young et al, 1993a; 1994) which accounts for their better bioavailability. As
the anticoagulant response to a fixed dose of LMWH is more predictable, the need
for their close laboratory monitoring should be redundant.
In order to improve our understanding of the factors that determine the anticoagulant
response to heparin in the clinical environment, an in vivo model of heparin clearance
and recovery was established in the rabbit. Clearance of radiolabeled heparin from
plasma , recovery of its biological activity, tissue localisation of radiolabeled heparin,
and quantification and characterisation of excreted heparin were assessed in the rabbit
after i.v. bolus injections of various doses of UFH, and the findings were compared




One of 3 doses of UFH (20, 50 or 100 anti-factor Xa U/kg) was administered by
bolus i.v. injection to New Zealand White specific pathogen-free rabbits. Tracer
amounts of radiolabeled UFH were administered intravenously at the same time.
Serial blood samples were taken at various times over the next 60 minutes, when the
animal was killed. A post mortem examination was performed, the bladder urinary
volume was recorded, and representative samples of the spleen, liver, kidneys and
urine were removed. The same experiments were performed with the LMWH
enoxaparin.
Experiments were performed to assess the effect of LAH in vivo. Excess LAH (20-
fold molar excess : UFH) was administered by bolus i.v. injection either 10 minutes
prior to UFH (50 anti-factor Xa U/kg) or 15 minutes after it. Tracer amounts of
radiolabelled UFH were administered intravenously with the UFH. Eight animals in
total received LAH and UFH; each combination of LAH and UFH was administered
to 4 animals. Serial blood samples were taken at various times in the 60 minutes
following UFH administration, and PPP prepared. As a control, 2 rabbits were given
only LAH and the small amount of anti-factor Xa activity measured in the plasma of
these rabbits was subtracted from the anti-factor Xa activity measured in the plasma
of rabbits that received UFH and LAH.
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Clearance of 125I - labelled heparin
The disappearance of radiolabeled heparin from plasma was plotted as a function of
time and the elimination half-life (ti/2) was determined by linear regression analysis
after logarithmic transformation. The slope of the regression line which represents the
elimination phase is designated -|3 and ti/2 is 0.693/f} (Gillies et al, 1986).
Heparin recovery based on anticoagulant activity
The anti-factor Xa activity of heparin in each plasma sample was determined by
chromogenic substrate-based assays. To assess the amount of heparin that was bound
non-specifically to plasma proteins (reversible heparin binding) ex vivo, the anti-factor
Xa activity was measured before and after the addition of LAH.
Recovery of heparin in the first 20 minutes after heparin injection was calculated by
plotting the plasma heparin concentration as a function of time and measuring the
AUC using the trapezoidal rule method (Gillies at al, 1986). Analysis was restricted to
the first 20 minutes after heparin administration because most of the anti-factor Xa
activity of the lowest dose tested was cleared during this interval.
Quantification of organ radioactivity
The weight of each tissue sample was recorded and the amount of radioactivity in the
tissue was determined in the gamma counter. The total amount of radioactivity per
gram tissue was then calculated.
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Quantification of urinary radioactivity
The bladder urinary radioactivity was calculated from the bladder urinary volume
(obtained at post mortem examination) and the radioactivity in lOOpL urine after
radioactivity from unbound radiolabel had been subtracted.
Characterisation of urinary heparin
Excreted urinary 125I-heparin was separated using modified HPLC techniques and the
radioactivity from urinary radiolabeled heparin was plotted as a function of time. The
radioactivity-time profile was compared with those of non-metabolised radiolabeled
UFH and LMWH in rabbit urine and the approximate molecular weights of the
heparin fractions in the eluates containing peak radioactivity were determined.
RESULTS
Clearance of 12SI-labelled heparin
The elimination of radiolabeled heparin plotted as a function of time is shown in
Figure 1. The duration of the distribution phase (5 minutes) and the rate of
distribution were similar at all doses for both heparins. The plasma elimination half-
lives of tracer amounts of 125I-labelled heparin administered with various doses of
excess unlabeled UFH and enoxaparin are shown in Table 2. The elimination of 125I-
UFH was dose-dependent and increased as the dose of unlabeled UFH increased.
Thus, the ti/2 after administration of 100 anti-factor Xa U/kg was 2.2 times longer
than after 20 anti-factor Xa U/kg and 1.7 times longer than after 50 anti-factor Xa
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Figure 1A,B : Elimination half—lives of various doses of UFH (A)
and enoxaparin (B) in control rabbits. Results presented are mean
+/— SEM of 5 experiments.
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U/kg. In contrast, the elimination of 125I-enoxaparin showed some dose-dependency,
although the half-lives increased only slightly with the higher doses of enoxaparin.
Thus, the tm after administration of 100 anti-factor Xa U/kg was 1.4 times longer
than after 20 anti-factor Xa U/kg and only 1.1 times longer than after 50 anti-factor
Xa U/kg.
Table 2 : Plasma half-lives (minutes) of 125I-labelled heparin administered with
various doses of UFH and enoxaparin.
Dose Plasma half-life (minutes)*
(anti-factor Xa U/kg) UFH LMWH p value
20 10.1 ± 1.0 18.4 ± 0.6 0.0004
50 13.6 ±1.2 23.1 ± 1.0 0.0004
100 22.5 ± 0.7 26.1 ± 0.5 0.002
Values are mean ± SEM of 5 experiments.
* Plasma half-lives (ti/2) were determined by linear regression analysis of the
semi-logarithmic plot of plasma radioactivity v time.
Recovery of heparin ex vivo
At each dose of heparin administered, there was a non-significant trend for greater
non-specific protein binding of UFH than enoxaparin (Table 3).
Assessment of ex vivo and in vivo use ofLAH
AUQ0-20 unbound) was significantly greater in animals that received LAH 10 minutes
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Table 3 : Protein-bound UFH and enoxaparin in plasma of control animals in
the first 20 minutes after adminstration of various doses of UFH and
enoxaparin.
Dose
(anti-factor Xa U/kg) UFH (%) * LMWH (%) t P value
Bound
20 39.6 ± 4.5 27.3 ± 9.1 0.3
50 33.7 ± 2.7 15.3 ± 6.6 0.03
100 22.4 ± 3.7 13.9 ± 5.7 0.2
Values are mean ± SEM of 4 or 5 experiments.
* Bound UFH is the amount of protein-bound UFH present in plasma in the
first 20 minutes after administration of various doses of UFH. It is calculated
from AUC(0-2o Total) - AUC(o-2o unbound) and is expressed as a percentage of AUC(o-2o
Total) •
f Bound LMWH is the amount of protein-bound LMWH present in plasma in
the first 20 minutes after administration of various doses of LMWH. It is
calculated from AUC(0.2o Total) - AUC(0.2o unbound) and is expressed as a percentage
Of AUC(0-20 Total) •
prior to 50 anti-factor Xa U UFH/kg compared with animals that received only 50
anti-factor Xa U UFH/kg (p <0.05, Table 4A). In addition, AUQ0-20 Total) in animals
that received only 50 anti-factor Xa U UFH/kg was compared with AUCV20 unbound) in
animals that received LAH 10 minutes prior to 50 anti-factor Xa U UFH/kg (Table
4B). There was no significant difference in UFH recovery between animals that
received LAH ex vivo and ones that received LAH in vivo.
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Table 4A : Effect of LAH in vivo on recovery ofUFH from control animals.
Unbound UFH (U ml"1 .min)*
- LAH f + LAH $ p value
Control 9.5 ± 0.6 15.5 ± 0.7 0.0001
Values are mean ± SEM of 4 (+LAH) or 5 (-LAH) experiments.
* Unbound UFH is the amount of unbound UFH in plasma in the first 20
minutes after administration of 50 anti-factor Xa U UFH/kg. It is calculated
from AUC(0-20 Unbound) •
f 50 anti-factor Xa U UFH/kg were administered to rabbits in the absence of
LAH.
$ 50 anti-factor Xa U UFH/kg were administered to rabbits 10 minutes after
LAH (20-fold molar excess : UFH) had been administered.
Table 4B : Comparison of ex vivo and in vivo quantification of reversible UFH
neutralisation.
LAH ex Vivo LAH in Vivo
Total UFH Unbound UFH
(U ml"1 .min) * (U ml"1 .min) f p value
Control 14.2 ± 0.6 15.5 ± 0.7 >0.1
Values are mean ± SEM of 4 or 5 experiments.
* Total UFH is the total amount of UFH in plasma in the first 20 minutes after
administration of 50 anti-factor Xa U UFH/kg and is calculated from AUC(o-2o
Total) •
f Unbound UFH is the amount of unbound UFH in plasma in the first 20
minutes after administration of 50 anti-factor Xa U UFH/kg to animals that
received LAH (20-fold molar excess : UFH) 10 minutes prior to the UFH. It is
calculated from AUC(0.2ounbound).
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Clearance of radioactivity and anticoagulant activity after LAH in vivo
When LAH (20-fold molar excess : UFH) was administered 15 minutes after UFH (50
anti-factor Xa U/kg), the resulting increase in plasma UFH concentration was not
acccompanied by an increase in the amount of radiolabelled UFH in plasma (Figure
2). After LAH administration, there was an almost 70% increase in anti-factor Xa
activity (from 0.47 ± 0.03 U/ml immediately before LAH administration to 0.79 ±
0.13 U/ml 5 minutes after LAH administration; p = 0.06). In contrast, there was no
significant increase in the amount of radiolabelled heparin recovered in the plasma
(17.0 ± 1.6 % of the total radiolabelled dose injected was present immediately before
LAH administration and 17.7 ± 1.4 % was present 5 minutes later; p = 0.75). In
addition, the administration of LAH in vivo resulted in an increase in the half-life of
radiolabelled UFH such that its half-life was significantly longer than in the absence of
LAH (13.6 ± 1.2 v 38.9 ± 0.9 mins, p<0.01) and was even greater than a comparable
dose of enoxaparin (38.9 ± 0.9 v 23.1 ± 1.0 mins, UFH+LAH v enoxaparin) (Figure
2).
Tissue localisation of radiolabelled heparin
Unfractionated heparin
On a per organ basis, the liver accumulated the highest levels of radioactivity at all
doses of UFH administered, with (11.6 ± 1.7)% to (30.8 ± 7.2)% of the total
radiolabelled dose injected accumulating in the liver (Figure 3A). Localisation of






















Figure 2 : Effect of LAH in vivo on UFH clearance and recovery.
LAH was administered 15 minutes after a bolus i.v. injection of
50 anti-factor Xa U/kg of UFH to control animals. Results
presented are mean +/— SEM of 4 experiments.
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radioactivity detectable decreasing as the dose of carrier UFH increased. Localistion
of radioactivity in the kidney was dose-independent, with no reduction in radioactivity
detectable as the dose of carrier UFH increased (Figure 3A).
Low molecular weight heparin
On a per organ basis and on a per gram basis, the kidney accumulated the highest
levels of radiolabelled LMWH at all doses of carrier LMWH administered (Figure3B).
On a per organ basis, the kidney accumulated (8.1 ± 0.5)% of the total dose of
radiolabelled enoxaparin injected, and thus approximately 16% of the total injected
dose of radiolabelled enoxaparin localised in renal tissue. Localisation of radioactivity
in the kidney was dose-independent, with no reduction in radioactivity detectable as
the dose of carrier LMWH increased. Localisation in the liver and spleen was
dramatically less than in the kidney, but in contrast to renal uptake, RES uptake was
dose-independent (Figure 3B).
Quantification of urinary radiolabelled heparin
Small amounts of radiolabelled UFH were excreted. The amount of bladder urinary
radioactivity was similar at all doses of UFH administered, and the mean amount of
radiolabelled UFH excreted into the urine of control animals within 60 minutes of
injection was (1.1 ± 0.2)% of the total dose injected. In contrast, at all doses studied
approximately 12 times more enoxaparin than UFH was excreted; the mean amount of
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Figure 3A,B : Localisation of radioactivity in liver, spleen and kidney
60 minutes after a bolus i.v. injection of various doses of UFH (A)
and enoxaparin (B) to control rabbits. Results presented are mean
+/— SEM of 5 experiments.
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Characterisation of urinary radiolabeled heparin
Chromatographic analysis of urine from control animals 60 minutes after a bolus i.v.
injection of 50 anti-factor Xa U UFH/kg indicated that UFH had undergone
degradation in vivo as the elution profile was similar to the non-metabolised iodinated
low molecular weight compound (Figure 4A,B). hi contrast, there was no evidence of
in vivo degradation of enoxaparin as the elution profile was unchanged compared with
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Figure 4 : FIPLC profile of non—metabolised UFH and enoxaparin
in rabbit urine (A), and radiolabeled excreted UFH and
enoxaparin in urine from control rabbits (B).
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DISCUSSION
The purpose of the study was to establish a reliable and reproducible in vivo model of
heparin pharmacokinetics and pharmacodynamics in order to identify the factors
responsible for the reduced heparin recovery observed in patients with high heparin
requirements. The rabbit was chosen as the in vivo model because its coagulation
system is similar to that of humans (Peyrou et al, 1997), and the size of animals
facilitated blood sampling and organ extraction. Three doses of heparin were used in
order to detect the effect of dosage on the various characteristics under study. The
highest dose of UFH was chosen as it is equivalent to the loading dose administered
by bolus i.v. injection to patients at the initiation of anticoagulant therapy, and is
similar to the dose of UFH that is required to saturate the cellular clearance
mechanism (Caranobe et al, 1985; Boneu et al, 1987a).
The disappearance of tracer amounts of radiolabeled heparin administered with
various doses of excess cold (unlabelled) heparin was used to assess the clearance of
heparin from the intravascular compartment. Previous work assessed the clearance of
the biological activity of heparin from plasma (de Swart et al, 1982; Boneu et al,
1987a, 1987b) but this study has improved the clinical application of these
observations by assessing the clearance of heparin that has antithrombotic activity,
irrespective of whether or not it has an anticoagulant effect.
The clearance of radiolabelled UFH was dose-dependent, and the half-life increased as
the dose of excess cold heparin was increased. In contrast, the clearance of
radiolabelled enoxaparin was largely dose-independent, and the half-life increased only
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slightly with the dose of unlabelled LMWH. At each dose studied, the half-life of
enoxaparin was longer than that of UFH because the renal clearance of therapeutic
doses of LMWH is slower than the cellular clearance of UFH (Caranobe et al, 1985).
As anticipated, this difference was least marked with the highest heparin dose because
at this dose a significant proportion of UFH has to be cleared through the slower renal
route as the cellular mechanism is saturated (Boneu et al, 1987a, 1987b). These
results agree with earlier findings and confirm the reproducibility and reliability of this
animal model.
UFH binds to a number of plasma proteins in normal plasma (Lane, 1989) and only
about 50% of its anticoagulant activity is recovered when it is added in vitro to
normal plasma (Young et al, 1993a). The recovery of UFH is further reduced when it
is added in vitro to patients' plasma because of non-specific binding to plasma
proteins (Young et al, 1993b, 1994). In contrast, LMWH exhibits less plasma protein
binding and at least 80% of enoxaparin is recovered in vitro from normal plasma
(Young et al, 1993a, 1994). This study allowed similar observations to be made in
vivo, although the difference between the two heparins in vivo was less striking than
in vitro. Fifteen to 30 percent of enoxaparin was reversibly bound in vivo to plasma
proteins which was comparable with in vitro findings, but only 20 to 40 percent of
UFH was inactivated by non-specific binding to plasma proteins in vivo. This
inconsistency may arise from differences between the in vivo and in vitro binding
kinetics of UFH and plasma proteins which do not occur with enoxaparin. However,
the in vivo and in vitro findings are consistent as enoxaparin exhibits less non-specific
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plasma protein binding than UFH. Further studies are required to determine if this
explains why patients with thrombosis treated with LMWH exhibit a less variable
dose-response than those treated with UFH (Handeland et al, 1990).
LAH has been used extensively as an in vitro and ex vivo tool to determine the extent
of reversible heparin neutralisation by non-specific plasma protein binding (Young et
al, 1992, 1993a, 1994). Previous observations have been extended by the present
novel use of LAH in vivo. This study has shown that LAH in vivo improves UFH
recovery by displacing UFH from binding sites, and the extent of reversible heparin
neutralisation that occurs in vivo can be assessed reliably ex vivo/in vitro using LAH.
When LAH was given after UFH, it produced a marked increase in anticoagulant
activity that was not accompanied by an increase in the amount of radioactivity
present in plasma. These findings suggest that at the dose of UFH studied, the
increase in anticoagulant activity after in vivo LAH administration is the result of
displacement of UFH from circulating heparin binding proteins and is not caused by
displacement of UFH from cellular sites. There are two potential explanations for
these findings, namely that when given in clinical doses (i.e. 50 anti-factor Xa U/kg),
UFH does not exhibit reversible binding to endothelial cells or macrophages in the
RES. Alternatively, UFH is rapidly internalised by the cells of the RES and is thus
inaccessible to displacement by LAH. This latter explanation appears the more likely
as macrophages have been shown to internalise and degrade both UFH and a LMWH
derivative (Bleiberg et al, 1983; Stehle et al, 1992).
The in vivo administration of LAH after UFH not only caused an increase in plasma
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anticoagulant activity but also resulted in a significant prolongation of the half-life of
UFH such that the clearance of radiolabelled UFH in the presence of LAH was slower
even than the clearance of a comparable dose of enoxaparin. This suggests that in the
presence of LAH, UFH can no longer be cleared by the cellular route and must now
be cleared predominantly by the slower renal route. Identification of the principal
components of the cellular mechanism of heparin clearance, and the effect of LAH in
vivo on the uptake of radiolabelled UFH by these components is required to
determine if this is indeed the case.
This study confirmed the previous observation that the principal organ of
accumulation of UFH-derived radioactivity is the liver (Dawes and Pepper, 1979). It
is established that phagocytic macrophages are widely distributed in the liver and
spleen, and many are fixed to endothelial structures lining the sinusoids of these
organs. An important role of the fixed macrophage is to clear unwanted particulate
matter from the circulation. The findings in this model agree with earlier in vitro
(Bleiberg et al, 1983; Falcone, 1989) and in vivo (Stehle et al, 1992) studies that
proposed a macrophage-mediated receptor-dependent mechanism of UFH uptake by
the liver. The results support the proposal that the principal organs of the RES, the
liver and spleen, play a major role in the removal of UFH from the blood and extend
previous findings by demonstrating in vivo that the uptake of UFH by the RES is
dose-dependent, or saturable, while the uptake of LMWH is also saturable but is
minimal. In contrast, the main organ of localisation of radiolabelled enoxaparin is the
kidney. Thus, 60 minutes after injection, about 16% of injected radiolabelled
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enoxaparin is localised in renal tissue and about 15% has been excreted in the urine in
a non-metabolised form. These results agree with those of other workers who
reported that LMWH is eliminated mainly from plasma via renal excretion (Boneu et
al, 1987b; Palm and Mattsson, 1987b; Stehle et al, 1992) and extend these
observations by demonstrating in vivo that the mechanism of renal clearance is
associated with uptake of LMWH by renal cells. This can probably best be explained
by a model in which a substantial proportion of LMWH that passes into the
glomerular filtrate is taken up by renal cells before being excreted into the urine. The
identity of these renal cells is uncertain, but a subgroup of mesangial cells has been
described which is situated in the glomerulus and has phagocytic properties (Anderson
and More, 1982), and could be responsible for the renal uptake of LMWH.
Approximately 12 times more radioactivity was measured in urine from animals that
received enoxaparin compared with UFH. This finding confirms those of a previous
study that showed that tritium-labelled preparations of another commercial LMWH
(Fragmin) are eliminated from plasma predominantly by renal excretion while
elimination of UFH is predominantly by metabolic clearance through the liver (Palm
and Mattsson, 1987b). These observations confirm the use of iodinated heparin
preparations as being a reliable method for assessing heparin pharmacokinetics in the
rabbit.
There is a lack of a reliable chemical method for the direct measurement of
administered heparin in biological fluids. Metachromatic assays have been used (Levy
and Jaques, 1978; Gundry et al, 1984) but they are only suitable for tests on purified
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materials and are insufficiently sensitive for investigations at the lower dose regimens
now used therapeutically (Johnson and Mulloy, 1976). A competitive binding assay
has been described which measures concentrations of administered heparin in urine
(Dawes et al, 1985). However, the urine must firstly be deionised by dialysis and the
low molecular weight cut-off dialysis tubing required (Mw 3,500) will potentially
remove products of exogenous heparin catabolism. The urine must also be diluted to
prevent competitive binding by endogenous glycosaminoglycans, which raises the
detection limit above the concentrations expected in the animal samples. None of
these methods provides molecular weight analysis of excreted heparin fractions. In
this study, the approximate molecular weight of the excreted heparin compounds was
assessed using a novel adaptation of HPLC. Initial attempts at molecular weight
determination using standard A absorbance - time chromatograms were unsuccessful
due to the presence in normal rabbit urine of significant quantities of carbonate and
triple phosphate crystals (calcium carbonate monohydrate and ammonium magnesium
phosphate). This particulate material interfered with light absorbance and various
methods of removal and denaturation were unsuccessful. An alternative wavelength at
which AOD of heparin but not urinary metabolites could be measured was not found.
The presence of radiolabelled heparin compounds in urine was then exploited by
counting the gamma-radioactivity present in the eluates obtained after free radiolabel
had been removed by ethanol precipitation. Urinary radioactivity was detectable 60
minutes after a therapeutic dose of UFH had been administered by bolus i.v.
injection, and the UFH had undergone degradation in vivo as the elution profile was
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similar to the non-metabolised iodinated low molecular weight derivative. These
results agree with those of Dawes and Pepper (Dawes and Pepper, 1979) who found a
similar pattern of urinary radioactivity shortly after a therapeutic bolus injection of
UFH had been administered, and the excreted isotope-containing material was also of
low molecular weight (< Mw 1,000). They additionally found a second, larger peak of
urinary radioactivity 5-9 hours after the injection. It is likely that the first urinary
excretion coincides with the initial phase of heparin clearance, and is quantitaively
small as the predominant method of UFH clearance is by hepatic metabolism. The
second peak may be explained by release of heparin from sites of internalisation, such
as endothelial cells, but further experiments are required to confirm this and are
outwith the scope of this study.
Previous observations were extended by analysing urine from animals that had
received enoxaparin. Although urinary radioactivity was also detectable 60 minutes
after a bolus i.v. injection of enoxaparin, in contrast to UFH there was no evidence
from this study that LMWH had undergone in vivo degradation as the elution profile
was unchanged compared with the starting compound. Greater amounts of
radioactivity were detected, consistent with the renal route being the principal
clearance pathway. The most likely explanations for this lack of enoxaparin
metabolism are firstly that RES uptake is an essential first step in heparin catabolism,
and once internalised, heparin is metabolised before being broken down into
saccharides. It follows that enoxaparin is excreted intact as cellular uptake of LMWH
is minimal. If RES uptake of heparin is fundamental to its catabolism, blockade of
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cellular uptake will result in excretion of non-metabolised UFH. Further experiments
will be performed to determine if this is the case. Secondly, degraded enoxaparin
molecules may have been present in the urine but remained undetected because their
molecular size was below the detection limit of the method.
In conclusion, the observations recorded in this chapter confirm that the rabbit model
described provides a reliable method for assessing the pharmacokinetics and
pharmacodynamics of heparin in vivo.
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CHAPTER 3
EXPERIMENTAL ENDOTOXAEMIA IN THE RABBIT :




As has been explained in some detail in the Introduction to this thesis, heparin exerts
its anticoagulant effect by accelerating the AT Ill-mediated inhibition of blood
coagulation factors. To do this, heparin must bind to AT III through a unique
pentasaccharide binding sequence with high affinity for AT III which is present in
approximately one-third ofmolecules (Choay et al, 1983; Lindahl et al, 1979; Hook et
al, 1976; Lam et al, 1976). Heparin also binds non-specifically and reversibly to other
plasma proteins which results in loss of its anticoagulant activity (Lane, 1989; McKay
and Laurell, 1980; Zammit et al, 1993), and reduction in the amount of heparin
available to bind to AT III. The proportion of anticoagulantly-active heparin that
binds non-specifically to plasma proteins can be measured by the in vitro use of
chemically-modified UFH, or LAH. This substance is devoid of anti-factor Xa activity
and when added to normal heparin-containing plasma it displaces anticoagulantly-
active heparin which is bound non-specifically to plasma proteins (Young and Hirsh,
1990; Young et al, 1993a).
There is wide variation in the anticoagulant response to a standard dose of UFH in
patients with thromboembolic disease. Previous studies have shown that reversible
heparin binding to plasma proteins is a major determinant of the anticoagulant
response in patients (Young et al, 1992), and it has been suggested that patients who
require large amounts of UFH do so because they have increased levels of heparin-
binding proteins which cause excessive heparin neutralisation (Young et al, 1992). In
contrast, LMWHs exhibit less binding to plasma proteins (Young et al, 1994) which
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may explain their less variable anticoagulant response to a fixed dose (Prandoni et al,
1992; Hull et al, 1992; Weitz, 1997).
Variability in anticoagulant response to heparin has been seen in a variety of patient
groups, including those with deep venous thrombosis (Cruickshank et al, 1991),
pulmonary embolus (Hirsh et al, 1976; Simon et al, 1978) and sepsis (Simon et al,
1978). An inflammatory process is common to all these groups irrespective of the
aetiology of the underlying disease. Inflammation is a curative process that results
from any form of tissue injury, be it infective, traumatic, immunological or adrenergic
in origin. It is accompanied by a diverse collection of local and systemic physiological
changes which together constitute the acute phase response (Morrison and Ulevitch,
1978; Billiau and Vandekerckhove, 1991). The systemic response is mediated by
cytokines released from activated macrophages that accumulate at the site of injury.
These hormone-like substances act on many distant tissues to induce fever, endocrine
changes, alterations in immune function, leucocytosis and changes in the
concentration of some plasma proteins, known collectively as the acute phase
proteins. This family of approximately 30 plasma proteins is generally produced in
increased amounts by the liver in inflammation. Increased plasma concentrations are
preceded by corresponding increases in hepatic mRNA concentrations, and the rates
of secretion of some proteins also increase (Koj, 1974; Castell et al, 1989). Some of
the heparin binding proteins such as fibronectin (Mosesson and Amrani, 1980),
vitronectin (Preissner and Miiller-Berghaus, 1987) and HC II (Tollefsen et al, 1982)
are also acute phase reactant proteins (Hagiwara et al, 1990; Seiffert et al, 1995;
Toulon et al, 1991), and so increased levels of these proteins during the acute phase
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response could contribute to variabilty in anticoagulant response and heparin
resistance. Against this proposition is the finding that the extent of reversible heparin
neutralisation by non-specific plasma protein binding is determined early on in the
disease process (Young et al, 1992). The potential for increased non-specific plasma
protein binding is present in patients' plasma within a few hours of the onset of
symptoms which is long before the de novo hepatic synthesis and release of acute
phase reactants could have occurred (Koj, 1974). Alternatively, others have suggested
that heparin requirements are increased in clinical pulmonary embolus because the
clearance mechanism is altered by the disease process such that the half-life is
significantly shortened (Hirsh et al, 1976; Simon et al, 1978).
In order to determine the relative contributions of reversible protein binding and
altered clearance to the variability in anticoagulant response and the phenomenon of
heparin resistance, an acute phase response was induced in rabbits and its effect on
plasma heparin recovery, clearance and metabolism was studied.
METHODS
Induction of the acute phase response
A well-characterised model of experimental endotoxaemia was employed to assess the
influence of the acute phase response on heparin pharmacokinetics and
pharmocodynamics in the rabbit (Mathison and Ulevitch, 1979; Mathison et al, 1988).
Initial dose-finding experiments were performed to establish the dosage of LPS
required to promptly induce clinical symptoms of advanced endotoxaemic shock
(Chapter 8). Administration of 10pg LPS/kg by bolus i.v. injection produced this state
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within 2 hours, and by 3 hours the animal was moribund. Severe symptoms were
produced more quickly with larger doses of LPS but this was considered unethical
and not pursued; smaller doses had not produced clinically advanced endotoxaemia
within 3 hours of administration.
Male New Zealand White specific pathogen free rabbits received lOpg LPS/kg by
bolus i.v. injection 2 hours before 1 of 3 doses of UFH (20, 50 or 100 anti-factor Xa
U/kg) was administered by bolus i.v. injection. Radiolabelled UFH in tracer amounts
was added to the excess unlabelled anticoagulant before administration. PPP was
prepared from serial blood samples taken at various time points over the next 60
minutes, and the animal was then killed. A post mortem examination was performed,
the appearance of the lungs and spleen recorded, the bladder urinary volume was
noted and representative samples of the spleen, liver, kidneys and urine were
removed. The same experiments were repeated with the LMWH enoxaparin. Control
animals were treated in the same way, but LPS was omitted. It was decided not to
administer a sham bolus i.v. injection of saline to these animals 2 hours prior to the
heparin to minimise animal handling and distress.
Clearance of 125I-labelled heparin
Plasma radioactivity was plotted as a function of time and the elimination half-life
(ti/2) was determined by linear regression analysis after logarithmic transformation.
The slope of the regression line representing the elimination phase is -3 and ti/2 is
0.693/p (Gillies et al, 1986).
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Heparin recovery based on anticoagulant activity
The anti-factor Xa activity of heparin in each plasma sample was determined by a
chromogenic substrate-based assay, from which the plasma heparin concentration was
determined.
Analysis of heparin recovery was restricted to the first 20 minutes after anticoagulant
administration because at the doses studied, most of the anti-factor Xa activity was
cleared during this period. Plasma heparin concentrations were plotted as a function
of time and the AUC was measured using the trapezoidal rule method (Gillies et al,
1986).
Quantification of organ radioactivity
The radioactivity per gram tissue was calculated from the radioactivity and weight of
each tissue sample.
Quantification ofurinary radioactivity
The bladder urinary radioactivity was calculated from the bladder urinary volume
(obtained at post mortem examination) and the heparin-bound radioactivity in IOOjiL
urine.
Characterisation of urinary radioactivity
Urinary radiolabeled heparin was separated using modified HPLC techniques and the
urinary radioactivity was plotted as a function of time. The approximate molecular
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weights of the heparin fractions in the eluates containing peak radioactivity were
determined.
RESULTS
Clearance of 125I-labelled heparin
The duration of the distribution phase (5 minutes) and the rate of distribution were
similar at all doses for each heparin type, and were not altered in the presence of
experimental edotoxaemia. There was no significant difference in the elimination
of 125I-UFH in LPS-treated rabbits compared with controls at each dose of excess
unlabelled UFH (Table 5). Similarly, there was no overall significant difference in the
elimination tV2 of 125I-enoxaparin in endotoxaemic animals compared with controls. At
the lowest dose administered, the half-lives in the two groups were significantly
different, but125I-enoxaparin was cleared more slowly from the circulation of
endotoxaemic animals compared with controls (Table 5).
Recovery of heparin ex vivo
The amount of UFH bound to plasma proteins was markedly higher in the LPS-
treated rabbits than in controls at each dose of UFH (Table 6A). The percentage of
UFH bound non-specifically to plasma proteins was significantly higher
(approximately 1.5-fold, p<0.05) in the LPS-treated animals that received 50 and 100
anti-factor Xa U/kg when compared to controls, and was close to significance
(p=0.08) in the group that received 20 anti-factor Xa U/kg.
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Table 5 : Plasma half-lives (minutes) of 125I-labelled heparin in control and
endotoxaemic animals after various doses of UFH and enoxaparin.
Dose Plasma half-life (minutes) *
(anti-factor Xa U/kg) Control LPS-treated ** p value
UFH 20 10.1 ±1.0 11.9 ±1.1 0.28
50 13.6 ±1.2 16.8 ±0.9 0.07
100 22.5 ±0.7 23.6 ±1.9 0.60
LMWH 20 18.4 ± 0.6 20.9 ± 0.7 0.04
50 23.1 ±1.0 24.0 ±0.5 0-45
100 26.2 ±0.5 24.4 ±0.9 011
Values are mean ± SEM of 4 or 5 experiments.
* Plasma half-lives (ti/2) were determined by linear regression analysis of the
semi-logarithmic plot of plasma radioactivity versus time.
** LPS was administered 2 hours before the heparin.
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Table 6A : UFH recovery in the first twenty minutes after administration of
various doses ofUFH to control and LPS-treated animals.
















Control 20 5.0 ± 0.6 8.4 ± 1.0 3.4 ± 0.7 39.6 ± 4.5 *
50 9.5 ± 0.6 14.2 ± 0.6 4.8 ± 0.4 33.7 ± 2.7**
100 32.9 ± 1.9 42.9 ± 3.4 10.0 ± 2.3 22.4 + 3.7**
LPS-treated 20 3.5 ± 0.7 8.1 ± 1.1 4.6 ± 0.7 56.8 ± 6.7 *
50 10.0 ± 1.5 17.6 ± 2.7 7.6 ± 1.2 43.4 ± 1.8**
100 28.9 ± 2.1 47.5 ± 6.4 18.4 ± 4.7 37.2 ± 5.5**
* p = 0.08 ** p < 0.05
In contrast, the recovery of enoxaparin was not altered by experimental endotoxaemia
(Table 6B). At each dose of enoxaparin administered, there was no difference in the
percentage of enoxaparin bound non-specifically to plasma proteins in LPS-treated
animals compared with controls (p>0.2, control versus LPS-treated, at each dose).
Tissue localisation of 125I-labelled heparin
Localisation of radioactivity in organs was essentially unaltered by experimental
endotoxaemia. The liver and kidney remained the principal organs of uptake of
radiolabeled UFH and enoxaparin respectively, and the amount of radioactivity that
accumulated in each organ in LPS-treated animals was unchanged when compared
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Table 6B : Enoxaparin recovery in the first twenty minutes after administration
of various doses of enoxaparin to control and LPS-treated animals.
12 3 4
Amount
Recovery Recovery plasma- % bound
Dose - LAH + LAH protein to plasma
(anti-Xa U/kg) (U ml"1. min) (U ml"1. min) bound proteins
(U ml"1 .min)
Control 20 4.4 ±0.4 6.3 + 0.9 2.0 + 0.8 27.3 ± 9.1 f
50 10.8 ±1.2 12.9 ±1.5 2.1 ±0.9 15.3 ± 6.6 f
100 26.6 ±6.6 27.7 ±5.5 3.0 ±1.2 13.9 ± 5.7 f
LPS-treated 20 5.2 ± 0.4 6.7 ± 0.6 1.6 ± 0.5 23.8 ± 6.6 f
50 10.0 ±0.7 13.6 ±1.1 3.7 ±0.7 26.4 ± 3.4 f
100 28.0 ±3.2 30.2 ±3.8 5.0 ±2.0 15.1 ± 3.9 f
f p > 0.2
Tables 6A,B : values are mean ± SEM of 4 or 5 experiments.
The amount of heparin recovered was determined as anti-factor Xa activity and
was calculated from the AUC for the first 20 min after administration of
heparin (Column 1). Excess LAH was added ex vivo to displace heparin from
plasma protein binding sites and the AUC again calculated (Column 2). The
difference between Column 1 and Column 2 is the amount bound to plasma
proteins (Column 3) and is used to determine the percentage of heparin bound
to plasma proteins (Column 4).
LPS was administered 2 hours before the heparin.
with control animals (Figure 5). At the lowest dose of UFH, there was a significant
increase in the amount of radioactivity in the spleen of LPS-treated animals compared
with controls (p<0.01). However, there was no difference between the control and
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Figure 5A,B : Localisation of radioactivity in liver, spleen and kidney
60 minutes after a bolus i.v. injection of various doses of UFH to
control (A) and LPS—treated (B) rabbits. LPS was given 2 hours
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D 20 anti—Xa U/kg
Y//1 50 anti-Xa U/kg
11111 100 anti—Xa U/kg
* p<0.01 control v LPS—treated
Kidney Liver Spleen
Figure 5C,D : Localisation of radioactivity in kidney, liver and spleen
60 minutes after a bolus i.v. injection of various doses of enoxaparin
to control (C) and LPS—treated (D) rabbits. LPS was given 2 hours
prior to the LMWH. Results presented are mean +/— SEM of 5
experiments.
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there was no difference in the amount of radioactivity in the liver and kidney of
endotoxaemic animals compared with controls (p>0.1 for each organ, at each dose,
excepting kidney at 50 anti-Xa U/kg, when p=0.02). Similarly, at the highest dose of
enoxaparin, there was a significant increase in splenic radioactivity in LPS-treated
animals compared with controls (p<0.01). Once again, there was no difference
between the control and endotoxaemic groups at either of the other 2 doses (p>0.1, at
each dose), and endotoxaemia did not alter the amount of radioactivity in the liver and
kidney when compared with control animals. The small increases in splenic
radioactivity in endotoxaemic animals at the lowest dose of UFH and the highest
dose of enoxaparin may therefore be regarded as being without biological
significance.
Quantification and characterisation of urinary 12SI-labelled heparin
Experimental endotoxaemia did not produce a qualitative or quantitative change in
excreted 125I-labelled heparin. Despite advanced endotoxaemia, the role of the RES in
heparin metabolism was preserved as in vivo metabolism of UFH continued (Figure 6)
and, as in control animals, the amount of bladder urinary radioactivity in LPS-treated
rabbits was dose-independent, and approximately 12 times more radiolabeled
enoxaparin than UFH was excreted (Table 7).
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Time (minutes)
Figure 6A : HPLC profile of non—metabolised radiolabeled
UFH in rabbit urine , and radiolabeled UFH in urine
from control and LPS—treated rabbits. LPS was
given 2 hours prior to the UFH.
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Time (minutes)
Figure 6B : HPLC profile of non—metabolised radiolabeled
enoxaparin in rabbit urine —■—, and radiolabeled enoxaparin
in urine from control and LPS-treated rabbits.
LPS was given 2 hours prior to the enoxaparin.
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Table 7 : Excretion of I125-labelled heparin in control and endotoxaemic rabbits
60 minutes after various doses of UFH and enoxaparin.
Bladder Urinary Radioactivity
Dose (% total dose) *
(anti-factor Xa U/kg) Control LPS-treated ** p value
UFH 20 1.1 ± 0.1 0.6 ± 0.3 0.3
50 0.8 ± 0.2 0.7 ± 0.2 0.7
100 1.4 ± 0.6 0.9 ± 0.1 0.3
(mean) 1.1 ± 0.2 0.8 ± 0.1 0.1
Fnoxaparin 20 12.0 ± 1.8 15.2 ± 0.4 0.2
50 14.7 ±1.1 11.5 ±2.7 0.3
100 15.3 ±2.2 11.7 ±1.7 0.2
(mean) 13.8 ± 1.0 11.8 ± 1.3 0.2
Values are mean ± SEM of 3 to 5 experiments.
* Bladder urinary radioactivity is the amount of radioactivity present in urine
60 minutes after a bolus i.v. injection of various doses of UFH or enoxaparin. It
is expressed as a percentage of the total injected dose of I125-labelled heparin
corrected for free I125.
** LPS was administered 2 hours prior to the heparin.
DISCUSSION
The relative contributions of non-specific plasma protein binding and altered clearance
to the variability in dose response to heparin and to the impaired anticoagulant
response observed in some patients with acute venous thromboembolism are
uncertain. In this study, the effect of acute inflammation on heparin clearance and
reversible protein binding was examined. Inflammation is a curative process that is
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common to all acute illnesses, and results from a variety of stimuli including infection,
tissue injury, neoplastic growth and immunological disorders. An established
experimental model (endotoxin administration) was employed to induce acute illness
in rabbits. This model has been shown to increase the level of heparin binding proteins
in rat plasma (Young et al, 1997) and to potentiate the development of venous
thrombosis in rabbbits (Bernat et al, 1994). Endotoxin was administered intravenously
in the form of LPS prepared from Salmonella minnesota Re595 bacteria. The dose
administered was in excess of that which has been shown previously to induce
maximal plasma levels of tumour necrosis factor (a major mediator of endotoxin-
induced injury) within 100 minutes of i.v. administration (Mathison et al, 1988). A
number of cell types including blood monocytes, tissue macrophages, neutrophils and
platelets have also been shown to be activated by LPS (Morrison and Ulevitch, 1978).
The results of this study show that the amount of UFH that is bound non-specifically
to plasma proteins is markedly increased in the plasma of LPS-treated rabbits. This is
similar to the effect of LPS on UFH recovery in the rat model (Young et al, 1997).
Therefore, reduced heparin recovery in acute illness can be attributed to an increase in
the plasma levels of heparin-binding proteins. In contrast, the recovery of enoxaparin
was unaffected by acute endotoxaemia. Thus, although enoxaparin binds to a modest
extent to plasma proteins in normal plasma, the results from this investigation indicate
that unlike UFH it does not bind to the heparin binding proteins that are released into
the circulation in response to LPS.
A dose of endotoxin was used that produced major multisystem perturbations within
2 hours of administration (Mathison et al, 1988). Since maximal hepatic synthesis of
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acute phase protein mRNA does not occur until 8 hours after initiation of the acute
phase response, and release of newly-synthesized acute phase proteins can therefore
only take place many hours after the onset of inflammation (Koj, 1974; Castell et al,
1989; Hurlimann et al, 1966) it may be concluded that the model of acute
inflammation used in this study predominantly assessed the extent of reversible
heparin binding to proteins that are released from storage sites in endothelial and
other vascular cells in response to endotoxin injury. It was felt essential to design a
model that would assess this aspect of reversible heparin neutralisation because the
tendency to increased heparin requirements occurs early in the disease process, before
plasma levels of acute phase reactants have risen (Young et al, 1992). As cytokine-
mediated release of PF4, lactoferrin and vWF from cellular storage sites occurs during
the inflammatory response (Fiedel, 1988; Billiau and Vandekerckhove, 1991; Schorer
et al, 1987) these heparin binding proteins (Rucinski et al, 1990; Maccarana and
Lindahl, 1993; Wu et al, 1995; de Romeuf and Mazurier, 1993) are implicated in
increased reversible heparin neutralisation in experimental endotoxaemia. A similar
situation may occur in humans when patients with thrombotic disorders show a
reduced anticoagulant response to heparin within a few hours of onset of their
symptoms. Finally, the findings from this study provide an explanation for the
observation that patients with thrombosis treated with LMWH exhibit a less variable
dose response than those treated with UFH (Handeland et al, 1990).
These results demonstrate that reversible heparin binding is an important mechanism
for reduced heparin recovery in acute illness, and that greater variability in
anticoagulant response to UFH than LMWH can be expected. In contrast, there is no
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evidence of increased heparin clearance in experimental endotoxaemia. Thus, the
elimination half-life of heparin in endotoxaemic rabbits was not different from that in
controls, even in the endotoxaemic animals that received UFH who had markedly
reduced recovery. This finding supports the observation that acute venous thrombosis
does not reduce heparin half-life (Hirsh et al, 1976) although it is at variance with the
finding that heparin clearance was reduced in clinical and experimental pulmonary
embolism (Hirsh et al, 1976; Chiu et al, 1977; Simon et al, 1978). The cause of this
inconsistency is not known but it may be ascribed to differences in the nature of the
thrombi found in venous thrombosis and pulmonary embolism. Further support for the
lack of a role for altered clearance in the variation in heparin dose-response is
provided by the absence of effect of experimental endotoxaemia on tissue localisation
of radiolabelled heparin, and the amount and characteristics of excreted radiolabeled
heparin, consistent with the absence of effect of endotoxaemia on half-life.
In summary, using an animal model of acute endotoxaemia, the phenomenon of
impaired heparin recovery has been demonstrated to be caused by an increase in the
concentration of heparin binding proteins. In contrast to UFH which showed a
significant reduction in recovery in endotoxaemic animals, the recovery of the LMWH
enoxaparin was not altered by endotoxaemia as it did not bind to the neutralising
proteins that increase after endotoxin treatment. There was no evidence that increased
heparin clearance contributes to the reduced heparin recovery observed in acute
illness. Although the results in rabbits may be quantitatively different from those in
humans, they are likely to be qualitatively similar. These findings suggest that the
variable anticoagulant response to UFH seen in patients with venous thrombosis is
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likely to be consequent upon alterations in plasma protein binding rather than heparin
clearance, and explain why patients with thrombosis exhibit a less variable dose-
response when treated with LMWH compared with UFH.
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CHAPTER 4
NOVEL IN VIVO APPLICATION OF A
LOW AFFINITY HEPARIN
TO IMPROVE HEPARIN RECOVERY
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INTRODUCTION
After almost two decades of research, LMWHs are now established as important
antithrombotic compounds that offer considerable advantages over their parent
preparation, the more traditional antithrombotic UFH. In the mid and late 1980s, it
was reported that low molecular weight preparations had a longer plasma half-life and
better bioavailablity at low doses than UFH (Frydman et al, 1988; Briant et al, 1989;
Bratt et al, 1986; Matzsch et al, 1987; Bara and Samama, 1988; Bradbrook et al,
1987), and a more predictable dose response (Handeland et al, 1990). These
pharmacokinetic and pharmacodynamic advantages are now known to result from
differences in plasma protein and endothelial cell binding that exist between the two
heparin preparations.
In 1979 the observation was made that normal plasma will neutralise the anti-factor
Xa activity of UFH but not of smaller molecular weight fractions of heparin
(Andersson et al, 1979). This neutralising activity of plasma was found to be caused
by plasma proteins which compete with AT III for heparin binding, and the non¬
specific binding was found to vary with the molecular size of the heparin. Many
plasma and platelet proteins with non-specific heparin binding activity have been
described, including PF4 (Lane et al, 1986; Holt and Niewiarowski, 1985), vWF
(Sobel et al, 1991), histidine-rich glycoprotein (Lane et al, 1986; Lijnen et al, 1983;
Peterson et al, 1987a) and lipoporoteins (Lane, 1989). It is likely that non-specific
protein binding contributes to the reduced bioavailability of UFH at low
concentrations, the variability in anticoagulant response to fixed doses in patients with
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thromboembolism (Hirsh et al, 1976) and to the laboratory phenomenon of heparin
resistance (Cruickshank et al, 1991; Young et al, 1992; Young et al, 1993a) In
contrast, LMWHs have lower affinity than UFH for many neutralising proteins,
including histidine-rich glycoprotein, PF4 (Lane et al, 1986) and vWF (Sobel et al,
1991). This relative lack of protein binding of the LMWHs gives them three important
practical advantages over UFH, namely superior plasma recovery when administered
in low doses, a relative lack of resistance to their anticoagulant effect, and a more
predictable anticoagulant response to weight-adjusted doses.
The molecular size of UFH and its fragments also influences binding to cellular
components. UFH binds to endothelial cells and is then internalised (Barzu et al,
1985), whereas the LMWHs do not bind to endothelial cells in culture (Barzu et al,
1984). The reduced binding of LMWHs to the endothelium contributes to their
greater bioavailability compared with UFH. In addition, the LMWHs show a reduced
tendency to bind to macrophages compared with UFH (Bleiberg et al, 1983) which
results in a longer plasma half-life. Therapeutic doses of UFH are cleared
predominantly by the saturable, or cellular, mechanism. The principal component of
this mechanism is the macrophage-rich RES and the liver is the main organ of UFH
uptake (Dawes and Pepper, 1979; Losito et al, 1977; Teien, 1977). In contrast,
LMWHs bind minimally to macrophages (Stehle et al, 1992), and so are cleared
predominantly by the renal route (Boneu et al, 1987b). This method of clearance is
slower than that of UFH when both heparins are administered at their usual
therapeutic doses (Boneu et al, 1987b; Caranobe et al, 1985), resulting in the longer
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half-life of LMWH compared with UFH.
Thus, the disadvantages of non-specific plasma protein binding and RES uptake have
been overcome by the LMWHs, produced commercially by controlled enzymatic and
chemical depolymerisation of UFH. The processes required for commercial
production are costly and the LMWHs are approximately 4 times more expensive to
use clinically than UFH. It would therefore be beneficial if the disadvantages of UFH
could be overcome in such a way that the benefits of the LMWHs could be bestowed
on UFH at a fraction of the cost. Various agents have been used in vivo which block
RES uptake (Bleiberg et al, 1983; Palm and Mattsson, 1987b; Stehle et al, 1992) but
any resulting prolongation in duration of biological activity is offset by reduced
intensity of activity consequent upon unopposed non-specific protein binding.
Therefore, in an attempt to improve UFH recovery, the molecular weight dependence
of both RES uptake and non-specific protein binding of UFH was exploited by the
novel in vivo administration of a chemically-modified UFH which is essentially devoid
of anticoagulant activity but identical in all other respects to the parent compound.
METHODS
Preparation of LAH
LAH was prepared from unfractionated porcine mucosal heparin by controlled
periodate oxidation and borohydride reduction (Casu et al, 1986) with minor




Excess LAH (20-fold molar excess : heparin) was administered by bolus i.v. injection
10 minutes prior to heparin (50 anti-factor Xa U/kg) and some animals were
pretreated with LPS. The following groups were studied :
1. LAH prior to heparin : excess LAH (20-fold molar excess : UFH) was
administered to 8 rabbits 10 minutes before a bolus i.v. injection of UFH (50 anti-
factor Xa U/kg). Tracer amounts of radiolabelled UFH were administered with the
unlabelled anticoagulant. Blood samples were taken at various times over the next 60
minutes, and PPP was prepared. Four of the animals had received LPS (10|ig/kg)
intravenously 120 minutes prior to the UFH. After 60 minutes, the animals were
killed. A post mortem examination was performed, the macroscopic appearance of the
spleen and lungs was recorded, the bladder urinary volume was noted and
representative samples of the spleen, liver, kidneys and urine were removed. The
experiments were repeated using enoxaparin in place of UFH.
2. Anticoagulant activity ofLAH in vivo : as a control, 2 rabbits received a bolus i.v.
injection of LAH (20-fold molar excess : UFH, assuming 50 anti-factor Xa U UFH/kg
had been administered) and 10 minutes later a further injection of physiological saline.
Blood samples were taken at various times in the 70 minutes after LAH
administration and PPP prepared. LPS had been administered to 1 of the animals 110
minutes prior to the LAH. After 70 minutes, the animals were killed. A post mortem
examination was performed and the macroscopic appearance of the lungs and spleen
was recorded. The same experiments were repeated using LAH at a dose of 20-fold
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molar excess : LMWH, assuming 50 anti-factor Xa U LMWH/kg had been
administered.
Clearance of 125I-labelled heparin
The disappearance of radiolabeled heparin was plotted as a function of time and the
elimination half-life (t!/2) was determined by linear regression analysis after logarithmic
transformation. The slope of the regression line which represents the elimination
phase is designated -(3 and ti/2 is 0.693/(3 (Gillies et al, 1986).
Heparin recovery based on anticoagulant activity
The anti-factor Xa activity of heparin in each plasma sample was determined by
chromogenic substrate-based assays, and the plasma heparin concentration was
determined from this value.
Recovery of heparin was calculated by plotting the plasma heparin concentration as a
function of time and measuring the AUC using the trapezoid rule method (Gillies et
al, 1986). Recovery was assessed both in the first 20 minutes and the full 60 minutes
after heparin administration.
Quantification of organ radioactivity
The total amount of radioactivity per gram tissue was calculated from the
radioactivity and weight of each tissue sample.
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Quantification of urinary radioactivity
Bladder urinary radioactivity was calclulated from the bladder urinary volume
(obtained at post mortem) and the radioactivity from 125I-labelled heparin in 100|iL
urine.
Characterisation of urinary heparin
Excreted radiolabeled heparin was separated using modified HPLC techniques and
the radioactivity from 125I-labelled heparin in urine was plotted as a function of time.
The approximate molecular weights of the heparin fractions in the eluates containing
peak radioactivity were determined.
RESULTS
Tissue localisation of radiolabeled heparin
Administration of LAH had a similar effect in control and endotoxaemic animals, and
so findings in control animals are considered representative. Localisation of
radiolabeled heparin in the liver and spleen was reduced significantly by pre-
administration of LAH (p<0.02 for each organ [-LAH v +LAH], Figure 7). However,
in absolute terms, pre-administration of LAH had a more profound effect on
localisation of 1251-UFH than 1251-enoxaparin. The absolute amount of radiolabeled
UFH that localised in the liver and spleen was reduced markedly by pre-administration
of LAH (Figure 7A). In contrast, pre-administration of LAH reduced the amount of
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Figure 7A,B : Localisation of radioactivity in liver, spleen and kidney
60 minutes after a bolus i.v. injection of 50 anti—Xa U/kg of UFH (A)
and enoxaparin (B). LAH was given 10 minutes prior to the heparin.
Results presented are mean +/— SEM of 4 | | or 5 Hill experiments.
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undetectable levels (Figure 7B).
Administration of excess LAH reduced dramatically the amount of 1251-enoxaparin
that localised in the kidney of control rabbits (p<0.001, [-LAH v +LAH], Figure 7B).
There was a trend towards a reduction in the amount of 125I-UFH that localised in the
kidney of control animals that received UFH and LAH compared with controls that
received UFH alone, but this reduction only reached statistical significance in
endotoxaemic animals (p<0.05, [-LAH v +LAH]). However, in absolute terms, pre-
administration of LAH prevented far more 125 I-enoxaparin than 125 I-UFH from
localising in the kidney.
Clearance of 125I-labelled heparin
Pre-treatment of animals with LAH resulted in a significant prolongation of the
elimination half-life of 125I-labelled heparin. In control animals, the half-life of 125I-
UFH was dramatically prolonged by RES blockade, and was approximately 2.1 times
longer in animals pre-treated with excess LAH compared with animals that received
only UFH (pcO.OOl, Table 8), while the half-life of enoxaparin in the presence of
LAH was only 1.3 times longer than in animals that received only enoxaparin (p<0.01,
Table 8). Experimental endotoxaemia did not alter the effect of RES blockade on the
clearance of 125I-labelled heparin. The elimination half-life of 125I-heparin in the
presence of excess LAH was similar in endotoxaemic and control animals (p=0.05,
UFH; p=0.5, enoxaparin; Table 8).
Loss of the RES as a route of heparin clearance had a greater effect on clearance of
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Table 8 : Plasma half-lives (minutes) of heparin-derived radioactivity in control
and endotoxaemic rabbits after 50 anti-factor Xa U/kg of heparin.
Plasma half-life (minutes) *
Control LPS-pretreated **
Heparin -LAH +LAH § p value -LAH +LAH § p value
UFH 13.6 ± 1.2 29.2 ± 1.4 t <0.001 16.7 ± 0.9 36.7 ± 2.8 f <0.001
LMWH 23.1 ±1.0 29.7 + 1.6$ <0.01 24.0 ± 0.5 27.7 ± 1.8 $ 0.07
Values are mean ±SEM of 4 or 5 experiments. f p=0.05 $ p=0.5
* Plasma half-lives (ti/2) are determined by linear regression analysis of the
semilogarithmic plot of plasma radioactivity v time.
** LPS was administered 2 hours before the heparin.
§ Excess LAH was given as the RES blocking agent 10 minutes prior to the
heparin.
UFH than enoxaparin, and the half-lives of the two heparins in control rabbits in the
presence of RES blockade became similar ([29.2 ± 1.4] v [29.7 ± 1.6] minutes, p =
0.8, Table 8). However, this similarity in clearance rates in the presence of RES
blockade was seen only in control animals as, unexpectedly, the elimination half-life
of 125I-UFH was longer than that of 125I-enoxaparin in endotoxaemic animals ([36.7 ±
2.8] v [27.7 ± 1.8] minutes, p = 0.04). This is in contrast to clearance rates in the
absence of RES blockade. Although UFH was cleared more quickly than enoxaparin
in the absence of excess LAH, the clearance rates were not affected by experimental
endotoxaemia and UFH was cleared more quickly than enoxaparin in both sick and
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well animals (Table 8).
Quantification of urinary 125I-heparin
The effect of RES blockade on urinary heparin excretion was not altered by
experimental endotoxaemia, and so the results from control rabbits are presented here
and are considered representative. Bladder urinary radioactivity in rabbits given LAH
prior to UFH was 10 times greater than in the absence of LAH (p<0.001, Table 9),
and was similar to levels in animals that received enoxaparin. In contrast, bladder
urinary radioactivity in rabbits given LAH prior to enoxaparin was only 1.6 times
greater than in the absence of LAH (p<0.05, Table 9).
Characterisation of urinary 125I-heparin
The elution profiles of urine from control and endotoxaemic animals in the presence
of RES blockade were similar, and results from control animals are considered
representative. RES blockade did not alter the molecular weight profile of excreted
125I-enoxaparin, as the elution profiles of urine from control animals given enoxaparin
in the presence and absence of RES blockade were similar (Figure 8B). In contrast,
the elution profile of urine from control animals given LAH prior to UFH was similar
to that of the non-metabolised iodinated starting compound (Figure 8A).
Recovery of heparin ex vivo
Pre-administration of LAH resulted in a significant improvement in heparin recovery
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Table 9 : Excretion of radiolabeled heparin in control rabbits in the presence
and absence ofRES blockade.
Bladder Urinary Radioactivity *
Heparin Type (CPM x 106)
(50 anti-factor Xa U/kg) - LAH + LAH ** p value
UFH 0.14 ±0.04 1.49 + 0.07 0.12.106
LMWH 2.28 + 0.33 3.64 + 0.37 0.02
Values are mean + SEM of 3-5 experiments.
* Bladder urinary radioactivity is the amount of radioactivity present in urine
60 minutes after a bolus i.v. injection of 50 anti-factor Xa U/kg of UFH or
enoxaparin, and is expressed in absolute terms (CPM x 106).
** LAH was given as the RES blocking agent 10 minutes prior to the heparin.
(Tables 10A-C). At each time point in the first 20 minutes after heparin
administration, the plasma heparin concentration was approximately 30 to 50% higher
in animals that received excess LAH before UFH or enoxaparin compared with those
that received only heparin. However, the improvement in recovery was more marked
in the middle and last tertiles following heparin administration, and most notably,
plasma UFH concentrations in the last tertile were improved by preadministration of
LAH from barely detectable levels to clinically significant concentrations (Figures
9A,B).
There was no difference in the extent of non-specific protein binding between the two
heparins in control animals who had received excess LAH, as there was no significant
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Time (minutes)
Figure 8A,B : HPLC profile of non—metabolised radiolabeled
UFH (A) and enoxaparin (B) in rabbit urine, and
radiolabeled UFH (A) and enoxaparin (B) in urine from control
rabbits in the presence and absence of LAH. LAH
was given as the RES blocking agent 10 minutes prior to a
bolus i.v. injection of 50 anti—Xa U/kg of heparin.
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Table 10A : Plasma UFH concentrations in the presence and absence of excess
LAH in control and endotoxaemic rabbits.
Plasma UFH concentration (U/ml) **
Time * Control LPS-treated f
(minutes) -LAH + LAH t p value -LAH + LAH t p value
5 0.43 ± 0.09 0.86 ± 0.09 0.01 0.54 ± 0.10 0.89 ± 0.09 0.04
10 0.45 ± 0.04 0.78 ± 0.02 <0.0001 0.45 ± 0.09 0.96 ± 0.07 0.004
15 0.39 ± 0.04 0.66 ± 0.03 0.001 0.42 ± 0.08 0.87 ± 0.06 0.004
20 0.32 ± 0.04 0.66 ± 0.02 <0.001 0.37 ± 0.08 0.82 ± 0.08 0.008
Values are mean ± SEM of 4 or 5 experiments.
* Time (minutes) after a bolus i.v. injection of 50 anti-factor Xa U UFH/kg.
** The plasma UFH concentration (U/ml) was determined by measuring the
anti-factor Xa activity ofUFH in each plasma sample.
f LPS was administered 2 hours prior to the UFH.
$ Excess LAH (20-fold molar excess : UFH) was given 10 minutes before the
UFH.
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Table 10B : Plasma enoxaparin concentrations in the presence and absence of
excess LAH in control and endotoxaemic rabbits.
Plasma LMWH concentration (U/ml) **
Time * Control LPS-treated f
(minutes) -LAH + LAH $ p value -LAH + LAH $ p value
5 0.63 ± 0.10 0.95 ± 0.04 0.04 0.51 ± 0.06 0.80 ± 0.07 0.03
10 0.52 ± 0.05 0.81 ± 0.08 0.02 0.51 ± 0.07 0.82 ± 0.14 0.04
15 0.45 ± 0.05 0.64 ± 0.03 0.02 0.54 ± 0.06 0.76 ± 0.08 0.07
20 0.43 ± 0.04 0.72 ± 0.05 0.004 0.44 ± 0.02 0.74 ± 0.09 0.02
Values are mean ± SEM of 4 or 5 experiments.
* Time (minutes) after a bolus i.v. injection of 50 anti-factor Xa U
enoxaparin/kg.
** The plasma LMWH concentration (U/ml) was determined by measuring the
anti-factor Xa activity of enoxaparin in each plasma sample.
f LPS was administered 2 hours prior to the enoxaparin.
| Excess LAH (20-fold molar excess : LMWH) was given 10 minutes before the
enoxaparin.
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Table IOC : Percentage increase in plasma heparin concentrations as a result of








5 33.1 ±7.1 46.3 ± 18.7 44.3 ± 2.0 43.0 ± 10.0
10 38.0 ± 2.9 51.2 ± 13.0 38.4 ± 8.1 42.5 ± 16.3
15 37.8 ± 5.4 50.5 ± 12.8 34.9 ± 5.8 35.3 ± 12.4
20 43.9 ± 2.7 51.1 ± 14.1 44.5 ± 6.8 36.8 ± 11.9
Values are mean ± SEM of 4 or 5 experiments.
* Time (minutes) after a bolus i.v. injection of 50 anti-factor Xa U/kg of
UFH or enoxaparin.
f LPS was administered by bolus i.v. injection 2 hours before the heparin.
$ The absolute plasma heparin concentration in the absence of LAH was
subtracted from the concentration in the presence of LAH, and the difference
was expressed as a percentage of the concentration in the absence of excess
LAH, giving the % increase caused by LAH.
Note : in the presence of excess LAH, the absolute plasma heparin concentrations at
each time point in the first 20 minutes after heparin administration were similar in all
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Figure 9A : Plasma heparin concentration (U/ml) in the
first 60 minutes after a bolus i.v. injection of 50 anti—Xa
U/kg of UFH to control rabbits in the presence (I and
absence # of RES blockade. LAH was given as the RES
blocking agent 10 minutes prior to the UFH. Results




Figure 9B : Plasma heparin concentration (U/ml) in the
first 60 minutes after a bolus i.v. injection of 50 anti—Xa
U/kg of enoxaparin to control rabbits in the presence %
and absence O of RES blockade. LAH was given as the
RES blocking agent 10 minutes prior to the enoxaparin.
Results presented are mean +/— SEM of 4 # or 5 O
experiments.
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difference in the improvement in recovery between UFH and enoxaparin, but the
difference in extent of protein binding between the two heparin types became apparent
in endotoxaemic animals (Table IOC). Moreover, in animals that received UFH, there
was a trend towards greater improvement in recovery in endotoxaemic animals
compared with controls, while the improvement in recovery in animals that received
enoxaparin was similar in control and LPS-pretreated animals (Table IOC).
DISCUSSION
The clinical effectiveness of UFH is limited by factors which determine its
pharmacokinetic and pharmoacodynamic characteristics. Of great importance is the
marked variation in UFH dose-response that is seen in patients with thromboembolic
disease (Hirsh et al, 1976). This variability is problematic and clinically important,
because a strong relationship exists between clinical effectiveness and anticoagulant
effect. Prospective studies have shown that the risk of suffering a recurrent venous
thromoembolic event is 10 to 15 times greater in patients who fail to achieve
therapeutic anticoagulation within 48 hours of initiation of heparin therapy (Hull et al,
1986; Basu et al, 1972) and patients who have suffered an acute myocardial infarction
are 20 times more likely to develop a left ventricular mural thrombus if
anticoagulation is inadequate (Turpie et al, 1989), and 6 times more likely to
experience recurrent angina pectoris or a second myocardial infarction (Kaplan et al,
1987). Consequently, the anticoagulant response to UFH must be monitored carefully
by a laboratory test and the dosage adjusted to produce a defined anticoagulant effect
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as quickly as possible after initiation of therapy.
The limitations of UFH have been overcome by the development of the LMWHs,
which have important differences in their plasma protein and endothelial cell binding
characteristics when compared with UFH. LMWHs are fragments of commercial
grade UFH produced by either chemical or enzymatic depolymerisation.
Depolymerisation leads to some loss of the original catalytic activity (Jordan et al,
1982) with the ability to catalyse thrombin inhibition decreasing to a much greater
extent than the ability to catalyse the inhibition of factor Xa (Andersson et al, 1979;
Ofosu et al, 1990; Thunberg et al, 1979). The relative importance of anti-factor Xa
and anti-IIa activities in exerting an antithrombotic effect remains unresolved. Some
observations suggest that the most important action of UFH and the LMWHs in
exerting their anticoagulant effects and possibly their antithrombotic effects occurs
through their ability to inactivate thrombin (Ofosu et al, 1988, 1989, 1990; Beguin et
al, 1988,1989). These observations are challenged by findings from experimental
animals (Ofosu et al, 1990; Boneu et al, 1993) and clincial trials that suggest that both
the anti-factor Ha and anti-factor Xa activities contribute to the antithrombotic effects
of the LMWHs.
It would be clinically advantageous to devise an anticoagulant that not only retains the
1:1 anti-Xa : anti-IIa ratio of UFH and so has optimal antithrombotic activity but also
has the recovery and clearance advantages of the LMWHs. This study has shown that
the disadvantages of UFH can be overcome by the novel in vivo use of excess
modified UFH which blocks the RES and binds non-specifically to plasma proteins,
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resulting in improved recovery and a longer half-life. Nevertheless, the increase in the
anticoagulant activity of UFH combined with the anticoagulant and antithrombotic
effects of LAH in vivo may be offset by an increase in bleeding complications, and
further studies are needed to assess the clinical applicability of this cheap and novel
form of pharmacokinetic and pharmacodynamic manipulation.
LAH has been used in vitro and ex vivo to assess the extent of reversible heparin
binding to non-specific plasma proteins (Young et al, 1992; Young et al, 1994). The
modified UFH has dramatically reduced anticoagulant activity which can be attributed
to a marked decrease in high-affinity AT III binding (Casu et al, 1986) such that it is
practically devoid of anti-factor Xa activity. However, this study has shown that when
administered in large amounts, LAH has significant anti-factor Xa activity. It is
concluded that this is due to the anticoagulant activity that is mediated through a low
affinity AT III binding site on the modified UFH which facilitates formation of a
ternary LAH-AT Ill-Xa complex but results in a much reduced rate of enhancement
of proteinase inhibition compared with high affinity heparin in keeping with the
hypothesis of Olson and Bjork (Olson and Bjork, 1994). An anticoagulant effect will
also be mediated through LAH-catalysed AT Hi-independent HC II activity
(Tollefsen, 1989) but this will cause anti-factor Ha activity which will not interfere
with the anti-factor Xa-based assessment of reversible protein binding used in this
study.
In order to modify the clearance mechanism of UFH and so prolong its biological
half-life, RES blockade was attempted. Various agents have previously been used as
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RES blocking agents. Pretreatment with high doses of uni- or multilamellar vesicles
will transiently reduce hepatic uptake of liposomes in the mouse (Kao and Juliano,
1981; Abra et al, 1980 ). Pretreatment with latex beads will slow hepatic clearance of
compounds but does not have a significant effect on reduction of hepatic uptake per
se (Kao and Juliano, 1981). I25I-labelled aggregated albumin is known to be
eliminated mainly by the RES (Benacerraf et al, 1957), but similarity of the radiolabel
with the preparation used in clearance experiments prevented its use in this study.
Compounds that are toxic to liver macrophages have also been used to block hepatic
uptake of molecules, including methyl palmitate (Tanaka et al, 1975) and dextran
sulphate (Patel et al, 1983) but the effect of these compounds on other clearance
mechanism components is uncertain. In addition, because heparins and dextran
sulphate are structurally and functionally similar, dextran sulphate is not a suitable
RES blocking agent when studying glycosaminoglycan metabolism. Thus, the
saturable nature of the cellular mechanism of UFH uptake was exploited by the novel
use of excess LAH in vivo as a RES blocking agent. The chemically-modified UFH is
produced by periodate oxidation followed by borohydride reduction. Although these
chemical techniques cleave the C2-C3 bond of non-sulphated uronic acid residues, the
molecular weight distribution, charge density, electrophoretic mobility and sulphate
content of the parent molecule are preserved (Casu et al, 1986). Sulphated
glycosaminoglycan receptors have been identified on the mouse macrophage cell
membrane (Bleiberg et al, 1983), but the mechanism by which heparin binds to the
receptor has not been described. This study provides evidence that heparin binding to
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the macrophage is not mediated through the unique high-affinity pentasaccharide
sequence necessary for AT III binding as this sequence is altered by the chemical
process required to produce LAH. As less uptake of LMWH than UFH by the RES
was found in this study, it is concluded that the macrophage receptor mechanism may
be dependent upon the chain length, extent of sulphation or anionic charge of the
molecule.
Earlier statements on the importance of the RES in UFH catabolism (Dawes and
Pepper, 1979) are supported by the finding that in the presence of RES blockade,
UFH was excreted unchanged compared with the starting radiolabelled material. This
suggests that either UFH is degraded after uptake by the RES, or UFH must be
metabolised by the RES before it can be degraded at a distant site.
In contrast to UFH, the main organ of localisation of enoxaparin was found to be the
kidney. This finding is consistent with other reports on the excretion of LMWH
(Boneu et al, 1987b; Palm and Mattsson, 1987b; Stehle et al, 1992). This study has
extended these observations by demonstrating in vivo that the mechanism of renal
clearance is associated with uptake of enoxaparin by renal cells, and it is proposed
that a substantial proportion of LMWH that passes into the glomerular filtrate is taken
up by renal cells before being excreted into the urine. When excess LAH was
administered in vivo, uptake of enoxaparin by renal cells was dramatically reduced.
The mechanism by which LAH prevented uptake of enoxaparin by renal tissue is
unclear. LAH was administered in very high concentrations and it is possible that only
the lower molecular weight moieties of LAH passed into the glomerular filtrate and
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competed with enoxaparin for renal uptake. Alternatively, the competing molecules in
the glomerular filtrate could have been metabolites of LAH that had been processed in
reticuloendothelial cells.
Not only did administration of LAH in vivo improve heparin recovery, but the
difference between recovery in the absence and presence of LAH in vivo increased
over time. This time-dependence results from the combination of reduced non-specific
plasma protein binding and altered clearance mechanisms. This study has previoulsy
shown that the anticoagulant activity of heparin in plasma increases after
administration of LAH in vivo as a result of displacement of heparin from circulating
plasma proteins. Also, heparin uptake by the RES is prevented by preadministration of
excess LAH, and so UFH clearance must now proceed by the slower renal route.
Therefore, preadministration of LAH not only improves the biological activity of
heparin in plasma but also facilitates increased duration of activity. As more UFH than
enoxaparin is bound non-specifically to plasma proteins and the RES is the
predominant route of UFH clearance, it follows that the effect of LAH in vivo on






UFH was discovered inadvertently in 1916 by McLean who, as a medical student, was
looking for a coagulant produced by the liver (McLean, 1916). The mechanism by
which UFH exerts its anticoagulant activity involving specific binding of UFH to the
naturally-occurring serine proteinase inhibitor AT III (Brinkhous et al, 1939;
Abildgaard, 1968; Rosenberg and Lam, 1979; Rosenberg and Bauer, 1994; Lindahl et
al, 1979; Hook et al, 1976) has been discussed in the Introduction section of this
thesis.
It is also known that UFH binds non-specifically to certain plasma proteins (Lane,
1989), including histidine-rich glycoprotein (Lijnen et al, 1983), PF4 (Holt and
Niewiarowski, 1985), vWF (Sobel et al, 1991) and vitronectin (Preissner and Miiller-
Berghaus, 1987), with loss of anticoagulant activity.
The wide variation in anticoagulant response to UFH found among patients with
thromboembolic disease (Hirsh et al, 1976) is clinically important because the
effectiveness of UFH depends upon achieving a clearly defined anticoagulant response
(Hull et al, 1986; Basu et al, 1972). As stated earlier, there is an increased risk of
recurrent thromboembolic events in patients in whom anticoagulation is suboptimal
(Hull et al, 1986; Turpie et al, 1989; Kaplan et al, 1987). The anticoagulant response
to UFH requires careful monitoring by laboratory testing to ensure that the dosage
may be adjusted to produce a defined effect, referred to as the therapeutic range.
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Low molecular weight heparins
LMWHs have been developed over the past 20 years to enable the limitations of
UFH, which have been described in the Introduction section of this thesis, to be
overcome. LMWHs are as safe and effective as UFH for the prevention and treatment
of venous thrombosis and pulmonary embolism both in hospital and at home
(Prandoni et al, 1992; Hull et al, 1992; Levine et al, 1996; Koopman et al, 1996;
Biiller et al, 1997), and in the treatment of unstable angina (Cohen et al, 1997). Like
UFH they exert their anticoagulant effect through interaction with AT III but only 15
to 25 percent of LMWH chains contain the unique pentasaccharide binding sequence
(Harenberg, 1990). In addition, fewer than half of the chains are of sufficient length to
bind to both AT III and thrombin (Jordan et al, 1980) and so they have greater
activity against factor Xa than thrombin. It is of significance that non-specific protein
binding of LMWHs is much less than of UFH and they have superior plasma recovery
when administered at low doses. It has been found possible to administer safely
weight-adjusted doses of the LMWHs for prophylaxis and treatment once or twice
daily by subcutaneous injection without the necessity of monitoring by laboratory
testing.
Variability in anticoagulant response
The factors responsible for the variation in heparin dosage requirments in patients
with venous thromboembolism have not been identified, but mechanisms that
determine heparin clearance and bioavailability have been implicated. The half-life of
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UFH was observed to be shorter in patients with pulmonary embolism than in patients
with venous thrombosis (Hirsh et al, 1976; Simon et al, 1978). It has been
demonstrated that experimental pulmonary emboli rapidly become covered with a
layer of platelets whereas the thrombi from which these emboli are derived are
relatively platelet-free (Chiu et al, 1977), and the possibility was raised that the
observed differences in heparin clearance in venous thrombosis and pulmonary
embolism were due to release of antiheparin activity from platelets. The differences in
clearance were confirmed in an experimental rabbit model of pulmonary embolism
(Chiu et al, 1977) but interestingly, there was convincing evidence that platelets did
not contribute to the shortened half-life in pulmonary embolism because heparin half-
lives in thrombocytopenic and non-thrombocytopenic animals were identical. In
addition, these experiments do not explain why variability in anticoagulant response is
seen in venous thrombosis as well as in pulmonary embolism.
When heparin binds to plasma proteins other than AT III, its anticoagulant activity is
reversibly neutralised (Lane, 1989). Young's group developed an ex vivo assay
system which measured the proportion of heparin which is reversibly neutralised by
binding to these plasma proteins (Young et al, 1992). They showed that reversible
heparin neutralisation is a major determinant of the heparin dose required to achieve a
therapeutic anticoagulant response, and that reversible binding to plasma proteins was
more marked in patients with venous thromboembolism who had increased heparin
requirements. This suggests that variability in dosage requirements is influenced by the
concentration of heparin-neutralising proteins which could differ among patients with
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venous thrombosis. The causative proteins were not identified, but the acute phase
proteins were considered likely candidates. However, as the tendency to increased
heparin requirements is present in the plasma of patients within a few hours of the
onset of symptoms (Young et al, 1992), it follows that acute phase reactants cannot
be responsible for increased heparin neutralisation as more than six hours must elapse
from induction of inflammation before release of newly-synthesized acute phase
proteins can occur (Koj, 1974; Castell et al, 1989; Hurlimann et al, 1966).
The purpose of this study was to determine the relative contributions of non-specific
plasma protein binding and altered clearance to the variability in dose response to
heparin and to the impaired anticoagulant response observed in some patients with
thromboembolism. A reproducible in vivo model of heparin pharmacokinetics and
pharmacodynamics was established using specific pathogen-free New Zealand White
rabbits. These animals were bred and born in a sterile environment to ensure that they
remain infection-free, as compared with farmyard rabbit strains traditionally used in
research that are plagued with a wide variety of infective diseases (Harkness and
Wagner, 1983; Flatt et al, 1974). It was considered important to use specific
pathogen-free animals to ensure that control conditions were optimised and that
control animals were not harbouring occult infection capable of inducing an acute
phase response with its associated protein upregulation, which would potentially alter
heparin recovery. By using these strains, alterations in heparin recovery could
justifiably be ascribed to exogenous factors, such as the effect of endotoxin or
differences between the heparin types. The rabbit was the preferred animal model. It is
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the most commonly used animal in thrombosis models because its coagulation system
is qualitatively similar to that of humans (Peyrou et al, 1997) and its size facilitates
multiple blood sampling and post-mortem organ extraction, both of which are difficult
in the rat and mouse.
The pharmacokinetics and pharmacodynamics of three doses of each heparin were
studied. In order to have clinical relevance, a dose of 100 anti-factor Xa U/kg was
chosen as this is similar to the amount of UFH that is given by bolus i.v. injection to
patients before an i.v. heparin infusion is started, and the cellular mechanism of
clearance is reported to be saturated by similar amounts (Caranobe et al, 1985; Boneu
et al, 1987a). Two other doses were assessed which were fractions of the highest dose
to ensure that a dose-response effect would be demonstrated if present in any of the
characteristics under study.
In this study, the effect of acute inflammation on heparin clearance and reversible
protein binding was examined. An established experimental model (endotoxin
administration) was used to induce acute illness in rabbits. This model has been shown
to increase the level of heparin binding proteins in rat plasma (Young et al, 1997) and
to potentiate the development of venous thrombosis in rabbits (Bernat et al, 1994). As
the tendency to increased heparin requirements may be present in patient plasma
within a few hours of the onset of symptoms, a dose of endotoxin was used that
produced major multisystem perturbations within 2 hours of administration (Mathison
et al, 1988). Since hepatic acute phase protein mRNA does not increase significantly
for 4 to 8 hours after acute phase induction and release of newly-synthesised acute
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phase proteins occurs many hours after the onset of inflammation (Koj, 1974; Castell
et al, 1989; Hurlimann et al, 1966), it is likely that the model of acute inflammation
used in this study predominantly assessed the extent of reversible heparin binding to
proteins that are released from storage sites in endothelial and other vascular cells as a
response to endotoxin injury. Thus, heparin binding proteins such as PF4 (Rucinski et
al, 1990; Maccarana and Lindahl, 1993), lactoferrin (Wu et al, 1995) and vWF (de
Romeuf and Mazurier, 1993) may be released from endotoxin-activated platelets,
neutrophils and endothelial cells, respectively, and a similar situation may be occurring
in patients with thromboses who develop a reduced response to heparin within a few
hours of onset of their symptoms. The presence of advanced endotoxaemia was
determined by the clinical status of the rabbit and our animals exhibited signs of severe
endotoxaemia within 2 hours of receiving a dose of LPS greater than that known to
induce maximal tumour necrosis factor production (Mathison et al, 1988). It was not
considered necessary to quantify markers of acute endotoxaemia such as interleukin-6
or tumour necrosis factor (Castell et al, 1989) to confirm the presence of advanced
endotoxaemia because of the convincing clinical status of the animals.
The results of this study have shown for the first time that the phenomenon of
impaired heparin recovery in vivo is caused by an increase in the concentration of
heparin binding proteins. There was no evidence that increased heparin clearance
contributes to the reduced heparin recovery observed in acute illness. Although the
results in rabbits may be quantitatively different, they are likely to be qualitatively
similar (Peyrou et al, 1997). This study suggests that variability in anticoagulant
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response to heparin seen in patients is likely to be caused by variations in plasma
protein binding rather than alterations in heparin clearance. In contrast to UFH which
showed a significant reduction in recovery in endotoxin-treated animals, the recovery
of LMWH was unaffected by acute endotoxaemia. Therefore, although the study
supported the contention that LMWH binds to a modest extent to proteins in normal
plasma, the results showed that unlike UFH it does not bind to the proteins released
from endotoxin-activated platelets, endothelial cells or neutrophils. These findings
provide an explanation for the observation that patients treated with LMWH exhibit a
less variable dose-response than those treated with UFH (Handeland et al, 1990).
Clearance kinetics
Heparin clearance can be assessed either by measuring the rate of disappearance of its
anticoagulant activity from plasma or by estimating the rate of disappearance of tracer
amounts of radiolabeled heparin administered with excess non-labelled heparin. The
latter method is based on the assumption that radiolabeled heparin is cleared from the
circulation in a manner identical to that of non-labelled anticoagulant. The major
anticoagulant effect of UFH and LMWH results from their ability to bind with high
affinity to AT III through a unique pentasaccharide binding sequence present on only
a minority of heparin chains. Heparin chains lacking this sequence have low affinity
for AT III and are devoid of anticoagulant activity in vitro. Despite the absence of an
anticoagulant effect, they still have antithrombotic activity as UFH has greater
antithrombotic action than high affinity fractions alone (Barrowcliffe et al, 1984).
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Therefore, the disappearance of the anticoagulant activity of heparin from the
intravascular compartment only assesses the clearance of fractions with high affinity
for AT III and excludes those fractions devoid of anticoagulant activity but which still
have antithrombotic activity and are clinically relevant. It is of greater clinical
relevance to measure the disappearance of radioactivity from plasma using tracer
amounts of radiolabeled heparin. The combined rate of clearance of all the different
heparin fractions is assessed by this technique because the ability of the radiolabel to
bind to the heparin chain does not depend upon chain length or the presence of a
specific binding sequence. For these reasons, tracer amounts of radiolabelled heparin
were used to determine the clearance kinetics of various doses of UFH and
enoxaparin.
In this study a similar clearance pattern was seen for each dose of heparin
administered, and this was true for each heparin type, in both control and endotoxin-
treated animals. At each dose, an initial rapid disappearance phase of about 5 minutes'
duration occurred which is consistent with an equilibration, or distribution, phase of
clearance when mixing of the drug in plasma, binding to plasma proteins and
distribution to another compartment (such as the endothelium) takes place, and data
from previous studies supports the occurrence of an initial rapid distribution phase (de
Swart et al, 1982; Olsson et al, 1963; Glimelius et al, 1978; Mahodoo et al, 1977).
For both UFH and enoxaparin, distribution was followed by a slower elimination
phase, and for each dose the half-life of UFH was shorter than that of enoxaparin,
results which support earlier work (Boneu et al, 1987a, 1987b). When plasma
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radioactivity was plotted semilogarithmically as a function of time, the linearity of the
relationship suggested that elimination was proceeding by a first-order process (Gillies
et al, 1986). This finding was similar for each heparin type at all doses, both in control
and endotoxin-treated animals, but is inconsistent with results from previous studies
of heparin kinetics. These studies did initially report that UFH disappeared
exponentially after i.v. administration (Olsson et al, 1963; Estes et al, 1969; Bjomsson
et al, 1982); these first-order kinetics were confirmed by others (Perry et al, 1974)
except Simon, who found that UFH removal in normal subjects was nearly linear,
indicative of a zero-order process (Simon et al, 1978). Moreover, most investigators
agreed that UFH half-life increased with dosage when the anticoagulant was
administered by bolus i.v. injection (Bjomsson and Levy, 1979; Olsson et al, 1963;
Bjomsson et al, 1982; Estes, 1970), although first-order kinetics dictate a constant
half-life. De Swart observed that the curve that describes the disappearance of a large
dose of heparin had a concave-convex shape, suggestive of a model that combines a
saturable (and exponential) and a non-saturable (and linear) mechanism of clearance
(de Swart et al, 1982). Boneu confirmed these observations and proposed that the
saturable mechanism had two main cellular components, endothelial and
reticuloendothelial cells, and that the non-saturable route of clearance was renal
(Boneu et al, 1987a, 1987b). There are several explanations for the differences in
clearance curves between this study and previous works. The majority of clearance
kinetics in Boneu's studies were based on the disappearance of anticoagulant activity
from plasma which is a measurement of the fractions with high affinity for AT III. In
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contrast, the clearance curves in this study were determined from clearance of
radiolabeled heparin. The clearance curve of 125I-labelled heparin is an amalgam of
the clearance curves of all the different heparin fractions, including those with both
high and low affinity for AT III which are known to be cleared at different rates
(Caranobe et al, 1986). This method of determining clearance was chosen as it is of
far greater clinical relevance than anticoagulant-based methods because it estimates
the half-life of exogenous antithrombotic material in plasma. In these circumstances
differences between results from the studies of Boneu et al and those from this
investigation are not perhaps surprising.
An alternative explanation may be obtained by consideration of the cellular mechanism
of clearance. Although the cellular mechanism is saturated at doses of between 75 and
100 anti-factor Xa U/kg in other systems (Caranobe et al, 1985; Boneu et al, 1987a),
in this model it remained the dominant mechansim of clearance at all the doses
studied. This study found that the clearance of antithrombotic activity was exponential
for both heparin types, but that the half-life of UFH was relatively dose-dependent
while the half-life of enoxaparin was relatively dose-independent and so consistent
with a first-order process. However, as UFH is thought to be cleared predominantly
by the cellular mechansim which follows first-order kinetics (de Swart et al, 1982;
Boneu et al, 1987a) and low molecular weight heparin by the renal mechansim which
follows zero-order kinetics (Boneu et al, 1987b), theoretically the half-life of UFH
should be dose-independent and that of enoxaparin should increase with increasing
dose. Although previous reports support both clearance mechanisms and processes,
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no explanation for these inconsistencies have been given. Based on previous
knowledge and the findings of this study, it would appear that basic physiological and
anatomical data is of paramount importance and must be incorporated into the
construction of a biologically meaningful kinetic model, while computerised curve
fitting programmes take secondary importance. Based on the findings in this study,
the following is proposed as an explanation of heparin clearance kinetics and is not
inconsistent with previous observations (Boneu et al, 1987a, 1987b; Goudable et al,
1986; Bara et al, 1985; Caranobe et al, 1985; Bergqvist et al, 1983; Aiach et al, 1983;
Thomas and Merton, 1982; de Swart et al, 1982; Dawes and Pepper, 1979). The
pharmacokinetic properties of UFH and LMWH determine that they are cleared from
the blood by a combination of a saturable and nonsaturable mechanism and that the
relative contributions of these two mechanisms depend upon the dose and type of
heparin injected. The terms 'saturable' and 'non-saturable' describe (respectively) the
limited and unlimited capacity that the components of each mechanism have for
heparin, and do not relate to the kinetics of the clearance processes. At low doses
within the therapeutic range, UFH is cleared primarily by the efficient saturable, or
cellular mechanism. As the dose increases, proportionally more UFH is cleared by the
slower, nonsaturable renal mechanism until the cellular mechanism is saturated and the
predominant route of clearance is renal. The half-life of UFH is dose-dependent
because although the kinetics of each clearance mechanism are exponential, the rates
of clearance differ between the two mechanisms. UFH is cleared by a combination of
the two mechanisms and as the dose increases, proportionally more UFH is cleared by
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the slower renal mechanism, and so the half-life of UFH increases until it
approximates that of LMWH at a dose of about 100 anti-factor Xa U/kg, when the
cellular mechanism is saturated and the renal route becomes the dominant clearance
route. In contrast, LMWH is cleared primarily by the non-saturable mechanism. The
contribution of the saturable mechanism to its clearance is negligible, irrespective of
the dose administered, as the cellular mechanism is saturated by very low doses of
LMWH. At therapeutic doses, the clearance of UFH by the cellular route is quicker
than the clearance of LMWH by the renal route, explaining why after comparable
doses the half-life of UFH is shorter than that of LMWH.
Clearance components
The components of the cellular mechanism of clearance have not been fully
determined, but there is good evidence that the RES, the endothelium and the kidneys
all play a role in the cellular, or metabolic clearance of UFH. In contrast, the major
component of LMWH clearance is the kidney and minimal clearance occurs by the
metabolic pathway (Monkhouse, 1954; Piper, 1947; Caranobe et al, 1985; Boneu et
al, 1987b). The liver and spleen were implicated in UFH metabolism when
intravenously administered UFH was found to accumulate in these organs before
being released back into the circulation fully desulphated and lacking biological activty
but retaining the molecular weight of the starting material (Dawes and Pepper, 1979).
The liver was confirmed as a metabolic site when it was observed that the biological
effect of UFH persisted for longer in hepatectomised rats (Losito et al, 1981).
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Receptors for sulphated glycosaminoglycans are found on the mouse macrophage cell
membrane (Bleiberg et al, 1983), and evidence exists that hepatic uptake of UFH may
be scavenger receptor-mediated involving liver macrophages and sinusoidal
endothelial cells (Stehle et al, 1992). Although O-desulphamidase activity has yet to
be described, a heparin N-desulphamidase has been demonstrated in various
mammalian tissue including rat spleen (Friedman and Arsenis, 1974). Hepatectomy
reduces the amount of desulphated glycosaminoglycan present in rat plasma after i.v.
administration, but desulphated material persists at a level greater than expected from
splenic desulphation (Wells and Dawes, 1995). This suggests that there is another site
of desulphation in vivo. Specific endothelial binding sites for heparin have been
identified (Barzu et al, 1985; Vannucchi et al, 1988) where bound glycosaminoglycans
are internalised and degraded to small fragments. Endothelial cells also produce fully
desulphated carbohydrate chains from a variety of radiolabeled glycosaminoglycans
(Dawes and Pepper, 1992) and it has been suggested that endothelial non-scavenger
receptor binding sites play a role in heparin uptake (Stehle et al, 1992). It therefore
appears that the RES and at least one other site, probably the vascular endothelium,
are responsible for desulphation ofUFH.
In contrast, although a small amount of LMWH is eliminated by metabolic clearance,
the major route of LMWH elimination is by renal excretion. At the doses used in this
study, about 15% of the total dose of injected radiolabelled enoxaparin had been
excreted within 1 hour of administration while in certain circumstances, up to 70% of
intravenously administered radiolabelled LMWH can be eliminated by the kidneys
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(Palm and Mattsson, 1987b).
The saturable nature of the metabolic pathway of elimination has been confirmed by
this study. For both UFH and LMWH, the amount of radiolabeled anticoagulant that
accumulated in the liver and spleen fell as the dose of excess unlabelled heparin
increased. Although proportionally less radiolabeled heparin accumulated in the
organs as the dose of heparin increased, the amount of radiolabeled heparin
administered at each dose was kept constant. Assuming that the clearance of
radiolabeled heparin is the same as that of the unlabeled molecule, this means that
the amout of unlabeled heparin that accumulated in the organs was similar at all 3
doses. Therefore, the liver and spleen were unable to significantly increase their
uptake of heparin despite more being available because their capacity for uptake was
finite, or saturable, at the doses under study. In contrast, renal uptake of each heparin
was unlimited. Because the amount of radiolabelled heparin was held constant, the
lack of change in the amount of radiolabelled heparin that accumulated in the kidneys
meant the amount of unlabelled heparin that accumulated increased with increasing
dose. This means that at the doses under study, renal capacity for heparin uptake is
unlimited and non-saturable. As expected, the RES was saturated by significantly
smaller amounts of enoxaparin than UFH, in agreement with the minimal role
proposed for the liver and spleen by Caranobe (Caranobe et al, 1985) and by Boneu
(Boneu et al, 1987b) in the elimination of LMWH.
Surprisingly, comparable amounts of radiolabelled UFH and enoxaparin were
associated with the kidney, which is inconsistent with previous work that suggested
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greater accumulation of LMWH than UFH (Palm and Mattsson, 1987b). Different
types of LMWHs were however used in the two studies. Several chemical and
enzymatic methods are used to produce the LMWHs which result in a heterogeneous
group of compounds with marked differences in their physico-chemical characteristics
(chemical structure, nature of the salt, molecular weight, molecular weight
distribution range and charge density pattern). The difference in renal accumulation of
the LMWHS may have been caused by differences in their physico-chemical
characteristics.
The results from this study suggest that UFH and LMWH are dealt with by the kidney
in different ways. Studies comparing radioactivity levels in urine and kidneys have
shown that LMWH elimination from plasma is by renal excretion into urine, while
elimination of UFH is mediated via metabolic, or cellular clearance with some
accumulation occurring in the renal tissue (Boneu et al, 1987a, 1987b; Palm and
Mattsson, 1987b). The identity of the renal cells which accumulate UFH is unknown,
and their function has not been fully determined. The kidneys have been proposed as
the site of degradation of the glycosaminoglycan once it has been fully desulphated
(Dawes and Pepper, 1979) but although a heparin-degrading endoglycosidase has
been described in rat spleen (Hook et al, 1977), a similar enzyme has not been found
in renal tissue to confirm that this is indeed the site of UFH degradation. There is
some evidence that the kidney also plays a role in heparin desulphation but promising
in vitro findings have not been supported by in vivo studies using nephrectomised rats
(Comper et al, 1994; Wells and Dawes, 1995). The major role of the kidney in the
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elimination of LMWH was confirmed in this study as about ten times more
radiolabeled enoxaparin than UFH was excreted into the urine. There was no
evidence that enoxaparin had undergone degradation prior to excretion whereas the
molecular weight profile of excreted UFH was similar to that of enoxaparin. A
possible explanation can be obtained if it is considered that only those heparin
fractions that have been completely desulphated may undergo subsequent
degradation. As hepatic uptake of LMWH is minimal, LMWH will remain sulphated
and so will not undergo degradation prior to excretion. This proposition is supported
by the observation that when large doses of UFH are administered intravenously to
rabbits, the majority of the anticoagulant cannot be desulphated as hepatic uptake is
saturated, and the UFH is excreted intact (Dawes and Pepper, 1979). In this study,
the in vivo use of LAH as a RES blocking agent had a similar effect, confirming the
importance of RES uptake in heparin catabolism. Finally, as with any experimental
method, the lack of detectable degraded enoxaparin may have resulted from lack of
adequate sensitivity of the detection method rather than through the absence of very
low molecular weight enoxaparin fractions per se. This is considered to be unlikely
but if so the amount of undetected degraded enoxaparin would be so low as to be of
minimal clinical significance.
Acute experimental endotoxaemia did not alter uptake of either heparin type by the
RES. This implies that the scavenger receptor-mediated uptake of heparin by the
macrophage cell system remains functionally intact and is not compromised by
endotoxaemia. This is in contrast to other cells whose functions are altered during
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endotoxaemia, including endothelial cells, platelets, neutrophils, monocytes and
fibroblasts (Billiau and Vandekerckhove, 1991). This has clinical implications as the
heparin-macrophage scavenger receptor interaction may account for several
antithrombotic properties of heparin which are independent of its anticoagulant
activity. In vitro and in vivo studies have shown that stimulation of macrophages by
heparin promotes profibrinloytic activity, possibly through increased secretion of
urokinase type plasminogen activator (Falcone, 1989; Markwardt and Klocking,
1977; Vinazzer et al, 1982; Bacher et al, 1992; Harenberg et al, 1990), and may play a
role in low density lipoprotein metabolism and endothelial cell/macrophage
interactions (Srinivasan et al, 1991; Lindstedt et al, 1992; Murata et al, 1988;
Harenberg et al, 1989). Thus, heparin-RES cell interactions appear to play a complex
and important role in the biology of the vessel wall with implications for physiological
and pathological mechanisms, and the findings of this study suggest that this role is
preserved during the insult of acute endotoxaemia and its associated challenge to
vessel wall integrity (Morrison and Ulevitch, 1978; Billiau and Vandekerckhove,
1991)
LAH - a therapeutic tool?
LAH was developed in order to provide a method of assessing the extent of reversible
heparin neutralisation by non-specific plasma protein binding in vitro and ex vivo
(Casu et al, 1986; Young and Hirsh, 1990). The anti-factor Xa activity of LAH is
<1.0 U/mg, but it has significant anticoagulant activity when administered in large
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amounts because anti-factor Xa activity can be mediated through a low affinity
binding site on the modified UFH (Olson and Bjork, 1994), and anti-factor Ha activity
can occur through LAH-catalysed, AT Ill-independent HC II (Tollefsen, 1989).
UFH has several pharmacokinetic and pharmacodynamic characteristics which hinder
its clinical usefulness. The LMWHs have similar anticoagulant efficacy compared with
UFH but are free from the characteristics of UFH that have restricted its clinical use.
Their main limitation is related to production-associated expense, with LMWH
costing 3 to 4 times more than a comparable dose of UFH. It follows that if the
advantages of the LMWHs could be bestowed upon UFH, the latter anticoagulant
would become a far more attractive anticoagulant at a fraction of the cost of LMWH.
Thus, factors determining the bioavailablity and clearance of UFH were manipulated
by the novel in vivo administration of excess LAH prior to UFH. In the presence of
excess LAH, UFH could no longer be cleared by the RES as cellular uptake
mechanisms were saturated by LAH. This suggests that scavenger receptor-mediated
uptake of glycosaminoglycans by macrophages did not occur through the
pentasaccharide binding sequence which is altered in the production of LAH. As chain
length differences are responsible for differences in heparin-endothelial cell binding
characteristics (Barzu et al, 1984), uptake by RES cells may be similarly dependent
upon chain length and/or degree of sulphation, neither of which is affected by the
LAH production process (Young and Hirsh, 1990). A significant increase in bladder
urinary radioactivity confirmed that the renal mechanism becomes the dominant
clearance method when the RES is saturated (Boneu et al, 1987a). The necessity for
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metabolic clearance prior to UFH catabolism was validated in this study when
radiolabeled fractions of a similar molecular weight profile to the non-metabolised
iodinated starting material were excreted in the presence of excess LAH.
Preadministration of LAH caused a significant improvement in plasma anticoagulant
recovery by providing an alternative substrate for non-specific protein binding. This
improvement was time-dependent with the difference in recovery in the absence and
presence of LAH increasing over time because with LAH preadministration, the
increased amounts of anticoagulantly-active UFH were eliminated by the slower renal
clearance mechanism. Confirmation of the clinical benefits of LAH resulting from this
improvement in recovery requires further experiments to ensure that the improvement
is not accompanied by an increased bleeding tendency.
It is of interest to note that excess LAH caused a significant decrease in the amount of
radiolabelled enoxaparin that accumulated in renal tissue but did not alter
accumulation of UFH, which suggests that UFH and LMWH interact with different
cell types in the kidneys. Renal cells involved in LMWH uptake may have a higher
affinity for longer than shorter chain lengths, and so preferentially take up LAH which
blocks LMWH uptake. In contrast, cells involved in UFH uptake may only interact
with heparin which has the unique pentasaccharide binding sequence, and so
preadministration of LAH will not alter these cells' uptake of UFH. Similar
experiments involving preadministration of LAH but using LAH labelled with a
different isotope to that of UFH and enoxaparin would provide useful information to





Since its first clinical application over fifty years ago, UFH has remained until recently
the preferred anticoagulant for the prophylaxis and treatment of a wide range of
conditions. However, despite its extensive clinical application, its pharmacokinetic and
pharmacodynamic characteristics remain poorly understood. Its clinical use is
hindered by its poor bioavailability after subcutaneous injection, and this feature
coupled with its short half-life determine that it is administered therapeutically by
continuous i.v. infusion. There is wide variation in the anticoagulant response to a
standard dose of UFH and the most extreme example of this is heparin resistance,
when large amounts of UFH are required to produce a therapeutic anticoagulant
response. For this reason, the anticoagulant response must be monitored closely by
laboratory testing, and the dose adjusted to achieve an anticoagulant response within
the therapeutic range. Factors responsible for the variability in dose response have not
been identified, but reversible heparin neutralisation by non-specific protein binidng
and increased heparin clearance in disease states have been thought to be implicated.
In contrast, the LMWHs offer several advantages over UFH. They can be
administered once or twice daily by subcutaneous injection which allows them to be
administered in the out-patient setting. They also produce a more predictable response
to weight-adjusted doses which obviates the need for labratory monitoring. They have
been shown to be as safe and effective as UFH in the prevention and treatment of
venous thrombosis, pulmonary embolism and unstable angina, and recently have been
used in the out-patient management of uncomplicated venous thrombosis and
pulmonary embolism.
In order to improve our understanding of heparin bioavailability and clearance, and in
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an attempt to identify the factors responsible for variation in UFH dose response, a
reproducible in vivo model of heparin pharmacokinetics and pharmacodynamics was
established in the rabbit. This has demonstrated that the phenomenon of impaired
heparin recovery is caused by an increase in concentration of heparin binding proteins.
The extent of reversible protein binding is substantially less with LMWH than UFH,
and in contrast to UFH which showed a significant reduction in recovery in acute
experimental endotoxaemia, LMWH does not bind to heparin binding proteins that
are released in reponse to endotoxin as its recovery was unaffected by acute
endotoxaemia. The study findings suggest that these heparin binding proteins are
unlikely to be acute phase reactants but are more likely to be proteins released from
activated platelets, endothelial cells or leucocytes. There was no evidence that
increased heparin clearance contributes to the reduced heparin recovery observed in
acute illness.
The novel in vivo application of LAH produced significant improvements in UFH
recovery and half-life. This has important clinical implications as the benefits of
LMWH could be gained for a fraction of its cost by using low affinity and
unfractionated heparins in combination. Although the results in rabbits may be
quantitatively different from those in humans, they are likely to be qualitatively
similar, and so it is probable that the variable anticoagulant response to heparin seen
in patients with venous thrombosis is caused by variable plasma protein binding rather
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UFH with MwAv 15,000 and anti-factor Xa activity of 160 U/mg and the LMWH
enoxaparin with MwAv 4,500 and anti-factor Xa activity of 100 U/mg (MwAv and
specific activities as stated by the manufacturer) were obtained from Rhone-Poulenc
Sante, France. SHPP was supplied by Pierce Chemical, Canada. Carrier-free 125I was
obtained from Dupont, USA. LPS obtained from Salmonella minnesota R595 by
phenol-chloroform-petroleum-ether extraction (Sigma Chemical Co., USA) was
suspended in lx sterile phosphate buffered saline (2mg/ml) and solubilized by
sonication. Human AT III (Cutter Biological, USA) and Sepharose (Pharmacia,
Canada) were used to prepare AT Ill-Sepharose affinity chromatography columns.
Progel TSK HPLC columns and PD-10 columns were purchased from Pharmacia,
Canada and Supelco, Canada, respectively. Specific pathogen free New Zealand
White male rabbits were used for all animal experiments (Charles River, Montreal).
Topical anaesthesia was achieved with EMLA cream (Astra Pharmaceutical Inc,
Canada) prior to insertion of indwelling intra-arterial and intravenous Angiocaths
(Becton Dickinson, USA) to which male luer lock plugs (Codan Medlon Inc, USA)
were attached. Butterfly cannulae used in euthanasia were obtained from
Venisystems, Abbott, Canada. Radioactivity quantification was carried out using a
gamma counter (Clinigamma LKB 1272, Fisher Scientific, Canada). Anti-factor Xa
assays were performed on the ACL automated coagulation analyser (Instrumentation





UFH was reacted with SHPP (Dawes and Pepper, 1979) and the product was labelled
with 125I based on the method of Greenwood (Greenwood et al, 1963). Commercial
sodium heparin (lOmg) was reacted with an excess of non-iodinated SHPP (lOmg) in
5ml of 0.05 M sodium borate (pH 9.2) at 4° C for 20 hours. Unreacted ester, at this
stage hydolysed to the acid, was removed by gel filtration in water on Sephadex G-25.
The material eluted at the void volume was chromatographed on protamine-agarose
to isolate the biologically active heparin derivatives. These were desalted, lyophilised,
and 300jig aliquots were labelled with 125I-Na. Twenty-five |iL of 125I-Na
(l|iL/0.1mCi) were added to 300pg of UFH-SHPP (lmg/ml dH20) followed by the
oxidising agent chloramine-T solution (lOpL of [5 mg chloramine/ml 0.4 M P04
buffer] solution). 0.4 M P04 buffer was prepared by adding buffer B (5.44 g KH2P04/
100ml dH20) to 500ml buffer A (28.43g Na2HP04 ,7H20/500ml dH20) until pH 7.4
was reached. The reaction was stopped 10-15 seconds after addition of chloramine-T
with 20|iL sodium metabisulphite (21mg NaS205 /3 ml 0.4 M P04 buffer, pH 7.4).
The reaction was then quenched with lOOpL sodium iodide solution (lOmg Nal/5ml
0.4 M P04 buffer, pH 7.4) and unreacted 125I-Na was removed by gel filtration in
halide-ffee buffer (0.4 M P04 buffer, pH 7.4) on Sephadex G-25 (10ml bed volume).
Equilibration of the gel was carried out with 0.4 M phosphate buffer, pH 7.4. The
elution pattern (which was reproducible) was determined by gamma-counting IOjjL
samples from each 500|iL eluate, and a non-radioactive discard fraction (2.5 ml) was
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followed by the 125I-UFH peak (1.5ml). In a typical process, approximately 20% of
the 125I-Na was incorporated and the iodinated UFH had a specific activity of
0.2 mCi/mg. The biological activity (as measured by anti-factor Xa assay) and
molecular weight distribution (as measured by gel filtration) of the radiolabelled UFH
were unchanged relative to the unlabelled starting material. The iodinated UFH was
stored at -70° C in siliconised microfuge tubes. Enoxaparin was iodinated in an
identical manner.
The iodinated heparin was reseparated if it was used in experiments more than two
weeks after the initial iodination. The material was reseparated by gel filtration in
phosphate buffered saline on Sephadex-G25 (10ml bed volume). 10|iL samples from
each 500|iL eluate were gamma-counted, and a non-radioactive discard fraction
(2.5ml) was followed by the 125I-heparin peak (1.5ml). The specific activity of the
reseparated iodinated heparin was then calculated prior to its use, and any unused
iodinated material was again stored in siliconised microfuge tubes at -70° C.
Preparation of LAH
LAH was prepared from unfractionated porcine mucosal heparin (157 USP units/mg,
Sigma Chemical Co., USA) by controlled periodate oxidation and borohydride
reduction according to the method of Casu (Casu et al, 1986) with minor
modifications (Young and Hirsh, 1990). UFH (500mg) was oxidized by sodium
periodate in an aqueous medium at 4° C for 24 hours. The reaction was stopped by
addition of ethylene glycol and dialysed against distilled water. The oxidized heparin
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was reduced by the addition of sodium borohydride and the solution was adjusted to
pH 3.0 to destroy excess borohydride and quickly readjusted to pH 7.0 to minimize
acidic conditions. After a second overnight dialysis against distilled water, the LAH
solution was adjusted to 1.0 M NaCl by the addition of solid salt. The product was
precipitated with 3 volumes of absolute ethanol, recovered by centrifugation (2,000 x
g at 4° C for 90 min) and air-dried.
In order to remove any remaining traces of high affinity material, the LAH was
subjected to affinity chromatography on an AT Ill-Sepharose column. Human AT III
(AT HI; 726 units) and CNBr-activated Sepharose were used to prepare the column
according to the manufacturer's instructions. The column (50ml bed volume) was
equilibrated with starting buffer (0.05 M Tris/HCl, pH 7.4 containing 0.15 M NaCl).
Approximately 60mg LAH was dissolved in 10ml starting buffer and pumped on to
the column followed by another 90ml starting buffer. The salt concentration was
switched to buffered 2.0 M NaCl and a further 90ml pumped through the column to
elute any high affinity heparin. The concentration of the resultant low affinity fraction
was measured by the protamine sulphate turbidimetric assay (Hatton et al, 1978). For
comparative purposes, lOmg UFH was subjected to affinity chromatography in a
similar manner. The flow-through material was recovered and re-applied to the re-
equilibrated column. This procedure was repeated for a total of 3 times and the
resultant low affinity fraction recovered and its concentration measured by the
protamine sulphate assay. Gel filtration chromatography was performed on Sephadex
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G-150 columns (Pharmacia). The samples (0.5ml) were adjusted to 1.0 M NaCl and
applied to the column (0.9 x 55cm) equilibrated with the same salt concentration. One
ml fractions were collected at a flow rate of 9 ml/h. The fractions were monitored by
determination of uronic acid by the carbazole reaction (Bitter and Muir, 1962). For
comparative purposes UFH was subjected to gel filtration chromatography in a similar
way.
The molecular weight distribution of LAH was within the range encompassed by
UFH, and the anticoagulant activities of LAH were essentially identical to that of
LAH separated from UFH by repeated affinity chromatography. Although the AT Ill-
dependent inhibition of factor Xa activity by LAH was almost completely abolished,
LAH retained anti-factor Ha activity through the AT Ill-independent, HC II pathway.
The anti-factor Xa activity of LAH was <1.0 U/mg, and the anti-factor Ha activity
was 20 U/mg.
Animal Studies
All procedures were carried out in accordance with the recommendations of the
Canadian Council on Animal Care for the care and use of experimental animals
(Canadian Council on Animal Care, 1993b), and approved by the Animal Rights and
Ethics Committee at McMaster University, Ontario, Canada. Specific pathogen free
New Zealand White male rabbits (2.5 - 3.0 kg) were used for all experiments. Newly-
acquired animals were allowed to acclimatise for a minimum of 6 days. The rabbits
were housed individually in stainless steel cages with a single-floor area of 0.50 m2,
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and 6 animals were contained in each holding room. The holding room temperature
was maintained at 16-20° C with a relative humidity of 40-50%, 10-20 air
changes/hour and a light cycle of 12 hours' artificial light in each 24 hour period. The
animals received 75-100g of pelleted commercial feed daily with a protein content of
14%. Autoclaved tin cans were provided as a source of environmental enrichment.
Experiments were performed in an area separate from the holding room. One hour
before insertion of indwelling i.v. and intra-arterial cannulae, the dorsal aspect of each
ear was plucked and a liberal application of EMLA topical anaesthetic cream (2.5%
lidocaine / 2.5% prilocaine) was placed over the central artery and marginal vein of
each ear, and covered. Animals were placed in restrainers and allowed to settle before
cannulae insertion. Control animals remained in the restrainers throughout the
experiment until euthanasia was completed. Animals that received LPS were placed in
the restrainers initially to facilitate insertion of cannulae and administration of agents.
They were then placed on a cushioned area of the floor and were nursed by the
handler throughout the experiment.
a) Control animals. Each rabbit was placed in the animal restrainer and allowed to
settle. EMLA cream was removed with 70% isopropylalcohol. A 22G Angiocath was
placed in the left central ear artery and secured, and a male luer lock plug was
attached to the distal end before the cannula was flushed with 1ml 0.9% NaCl through
the injection plug. The process was repeated for the right marginal ear vein. All
sampling and injecting was performed through the injection plugs via the arterial and
venous indwelling cannulae. Immediately before and after i.v. administration of study
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material, a bolus i.v. injection of 1ml 0.9% NaCl was given to ensure patency of the
cannula and to clear any residual injected material from the cannula. The animals were
given a bolus i.v. injection into the marginal ear vein of either 20, 50 or 100 anti-
factor Xa U/kg of UFH or enoxaparin in 1.5ml 0.9% NaCl to which a tracer amount
(lOuCi, <2 anti-factor Xa U) of the corresponding 1251-heparin had been added. Five
animals were used at each dose. The total amount of radioactivity administered was
determined in the gamma counter before injection (Appendix 1). After the mixture
had been injected, the empty syringe was weighed. Immediately before and at various
times (1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 and 60 minutes) up to 1 hour after
injection, blood samples were collected from the central ear artery into buffered 3.8%
sodium citrate (9 vol blood : 1 vol citrate ). Immediately before sampling, a bolus i.v.
injection of 1ml 0.9% NaCl was given via the central ear artery to confirm patency of
the cannula, and 1ml blood (dead space volume) was withdrawn from the cannula and
discarded. The blood samples were placed in siliconised microfuge tubes and put
immediately on ice, and the weights of the full and empty syringes were recorded.
Within 1 hour of sampling, PPP was prepared by centrifugation (1600 x g at room
temperature for 15 minutes). After 60 minutes, a 23G butterfly cannula was placed in
the left marginal ear vein and the animal was killed with a bolus i.v. injection of 3 ml
Euthanyl (sodium pentobarbital, 240 mg/ml). The animal was removed carefully from
the restrainer and a brief external examination of the heart was made. The animal was
then placed on the post mortem table in the dorsal recumbency position with the limbs
extended as far to the sides as possible. The abdominal and thoracic cavities were
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entered in turn through midline incisions. Representative tissue samples were taken
from the liver (right, anterior middle and left lobes), spleen and both kidneys. The
lungs and spleen were inspected for signs of haemorrhage and congestion before
samples were removed. The bladder wall was punctured under direct vision (20G
needle), bladder urine was aspirated, the bladder urinary volume was recorded and 4 x
lml urine samples were placed in siliconised microfuge tubes. The tissue samples were
air-dried and placed in polypropylene tubes, and the tissue samples and 3 of the 4
urine samples were stored at -70° C prior to analysis.
b) LPS-treated animals. Initial dose-finding experiments were performed to
determine the optimal dose of LPS required for the rapid induction of clinically-
advanced endotoxaemia (Table 11). After a bolus i.v. injection of LPS, the mean
arterial pressure was recorded at regular intervals through a pressure transducer
attached to an indwelling cannula in the left central ear artery and a constant record of
the animal's clinical condition was kept, paying particular attention to respiratory rate
and effort, appearance of conjunctivae, and the behavioural pattern of the animal.
Major organs were examined macroscopically at post mortem. The optimal dose of
LPS was found to be 10 |ig/kg. Rabbits were then pre-treated with LPS before
receiving either UFH or LMWH. After cutaneous anaesthesia had been secured and
cannulae placed (as above), rabbits received a bolus i.v. injection of LPS (10 ug/kg in
0.9% NaCl, final volume 1.5ml) into the right marginal ear vein. Two hours later, they
were given 1 of the 3 doses of UFH or LMWH with the corresponding 125 I-heparin
added (lOuCi, <2 anti-factor Xa U) in 1.5ml 0.9% NaCl as a single bolus i.v. injection
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into the marginal ear vein. Blood, tissue and urine samples were collected as for the
control animals. Five animals were used at each dose.
c) RES blockade. Sixteen rabbits received a bolus i.v. injection of LAH (20-fold
molar excess : UFH or LMWH in 0.9% NaCL, in final volume 1.5ml) into the right
marginal ear vein. Ten minutes later, 8 received a bolus i.v. injection of 50 anti-factor
Xa U/kg of UFH with 1251-UFH added (10 |iCi, <2 anti-factor Xa U) in 1.5ml 0.9%
NaCl into the marginal ear vein. The same number received a bolus i.v. injection of
LMWH with 1251-LMWH added (10 fiCi, <2 anti-factor Xa U) in 1.5ml 0.9% NaCl.
Four of each group of 8 animals were treated with LPS (as above) 110 minutes before
LAH administration. Blood, tissue and urine samples were collected as for the control
animals. Similar experiments were performed to evaluate heparin recovery and
clearance when excess LAH was given after heparin. Eight rabbits received a bolus
i.v. injection of 50 anti-factor Xa U/kg of UFH with 1251-UFH added (10 p.Ci, <2
anti-factor Xa U) in 1.5ml 0.9% NaCl into the right marginal ear vein. The same
number received a bolus i.v. injection of 50 anti-factor Xa U/kg of LMWH with 1251-
LMWH added (10 |iCi, <2 anti-factor Xa U) in 1.5ml 0.9% NaCl. Four of each group
of 8 animals were treated with LPS (as above) 120 minutes before heparin
administration. Fifteen minutes after heparin administration, they received a bolus i.v.
injection of LAH (20-fold molar excess : UFH or LMWH in 0.9% NaCl, final volume
1.5ml) into the marginal ear vein. Blood, tissue and urine samples were collected as
for the control animals.
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d) Anticoagulant activity ofLAH in vivo. The in vivo anticoagulant activity of LAH
given in 20-fold molar excess to a representative dose of UFH was assessed. Two
rabbits received a bolus i.v. injection of LAH (20-fold molar excess : UFH, assuming
50 anti-factor Xa U UFH/kg had been administered) into the right marginal ear vein.
One rabbit was treated with LPS (as above) 120 minutes before LAH administration.
Fifteen minutes before and 10 minutes after LAH administration, they received a bolus
i.v. injection of 1.5ml 0.9% NaCl into the same vein. Blood samples were collected
immediately before and at various times (5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60 and
70 minutes) after LAH injection. After 70 minutes, the animals were killed (as above).
The same experiments were repeated using LAH in 20-fold molar excess to LMWH,
assuming 50 anti-factor Xa U LMWH/kg had been administered.
Ethanol precipitation : determination of optimal conditions for estimation of
free 125I in plasma samples
A stock solution of 1251-UFH in 0.85M saline was prepared to an estimated specific
activity of 2.102 CPM 125 I-UFH/pL 0.85M saline. Twenty pL of 125I-UFH stock
solution were added to 1ml 0.85M saline in triplicate, the gamma radioactivity emitted
in 1 minute was counted and the mean value was calculated. Background radioactivity
was the mean gamma radioactivity emitted in 1 minute from 4 x 1ml 0.85M saline,
and the mean net radioactivity of the 1251-UFH stock solution samples was calculated
by subtracting the background radioactivity from the measured radioactivity of the
stock solution. Twenty pL of 125 I-UFH stock solution were added to 80|iL NRS,
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100|iL 0.85M saline and 600|iL 100% ethanol (3 volumes ethanol : 1 volume 125 I-
UFH/NRS/saline) in triplicate, left overnight at 4° C then centrifuged (1600 x g at
room temperature for 15 minutes). 500pL supernatant were added to 0.85M saline
(1:1) and the gamma radioactivity emitted in 1 minute was counted. The experiments
were repeated using increasing amounts of excess unlabelled UFH instead of NRS,
and the mixtures were allowed to precipitate at 4° C for 24 hours prior to
centrifugation at 1600 x g at room temperature for 30 minutes.
The conditions required for maximal precipitation of bound 1251 were as follows :
1 vol plasma : 1 vol 0.85M saline : 1 vol excess unlabelled UFH (lmg UFH/lOOjil
0.85M saline): 9 vol 100% ethanol, precipitated at 4° C for minimum of 16 hours then
spun at 1600 x g at room temperature for 30 minutes.
Pharmacokinetics
For each animal, the percentage of the injected dose of radioactivity present in 1ml
plasma was plotted as a function of time after transformation of radioactivity into
logarithmic values. The distribution and elimination half-lives {Un ct and Un P) were
determined by linear regression analysis (Appendix 1).
Quantification of tissue radioactivity
The tissue samples were stored in polypropylene tubes at -70° C prior to analysis.
They were thawed at room temperature and the tubes were weighed on an electronic
balance (Oertling, Avery Berkel, Canada) in the presence and absence of the tissue
149
sample. The weight of the tissue sample was the difference between the full and empty
polypropylene storage tube. The gamma radioactivity emitted in one minute by the
tissue (gross CPM) was counted. The machine background radioactivity was
calculated from the mean CPM of 4 x 1ml 0.85M saline samples; this value was
subtracted from the gross CPM of each tissue sample to give the CPM net of machine
background radioactivity (net CPM).
Tissue radioactivity was expressed either in absolute terms (as counts per minute per
gram tissue : CPM/g tissue), or in relative terms (as the percentage of the total dose
of radioactivity injected per gram tissue : % total dose/g tissue) (see 'Quantification of
urinary radioactivity' below).
Tissue-associated radioactivity was calculated using the following methodology :
i) Radioactivity per gram tissue (CPM/g tissue) : net CPM of tissue sample
weight of tissue samples
ii) With multiple samples from 1 organ, mean radioactivity per gram tissue (mean
CPM/g tissue): sum of i (CPM/g tissue) for all samples
number of tissue samples
iii) Tissue radioactivity per gram tissue as percentage of total dose of radioactivity
injected (% total dose/g tissue): i (CPM/g tissue) or ii (mean CPM/g tissue) x 100
Total Dose Injected (Figure IB, Appendix 1)
To assess if measured radioactivity in tissues was indicative of tissue-associated
radioactivity per se or merely a measure of radioactivity in blood trapped within
tissues, it was assumed that tissue-associated radioactivity was secondary to
radioactivity in trapped blood and expected values were calculated using established
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blood volumes of tissues from control and LPS-treated animals (Mathison and
Ulevitch, 1979) and measured plasma radioactivity levels at the time of tissue
extraction. The measured values (Y axis) were plotted against the calculated values
(X axis) (Phillips, 1992a) and the correlation coefficient was determined by linear
regression analysis (Figure 10), where r = slope of the regression of the Y variable on




r = Pearson coefficient
Xxy = sum of the cross products of deviations form the means of X and Y
distributions
N = number of such products
Sx and Sy : standard deviations of the two distributions
There was no correlation between predicted and measured tissue-associated
radioactivity values in the liver, spleen or kidney, confirming that the method for
quantifying tissue radioactivity accurately measured tissue-associated radioactivity per
se.
Quantification ofurinary radioactivity
Four x 1ml urine samples were placed in siliconised microfuge tubes after removal
from the bladder at post mortem. Three of the 4 samples were stored at -70° C prior
to determination of the molecular weight characteristics of the excreted radiolabeled
heparin. Samples from the fourth aliquot were used to determine the amount of
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determined by adding lOOpL urine to 900|iL 0.85M saline, in duplicate. The amount
of radioactivity from free 1251 in urine was determined by ethanol precipitation of
bound 1251-heparin; 100|iL urine were added to lOOpL 0.85M saline, lOOpL excess
unlabelled heparin (lmg/100pL 0.85M saline) and 900|iL 100% ethanol, in duplicate.
All of the urine samples were stored with the plasma samples at 4° C for 48 hours.
The ethanol precipitation samples were then centrifuged (1600 x g at room
temperature for 30 minutes) and 500pJL supernatant was added to 500|iL 0.85M
saline. The gamma radioactivity emitted in one minute from each sample (gross CPM)
was counted and the mean gross CPM of the duplicate samples was calculated. The
machine background radioactivity was calculated from the mean CPM of 4 x 1ml
0.85M saline samples; this value was subtracted from the mean gross CPM of each
pair of samples, giving the CPM net of machine background radioactivity (net CPM).
Bladder urinary radioactivity was expressed either in absolute terms as bladder urinary
radioactivity (CPM), or in relative terms as the percentage of the corrected total dose
injected (% total dose).
In animals that did not receive LAH in vivo, the calculated values for the total injected
doses of radioactivity (Appendix 1) in control and endotoxin-treated animals were the
same, and so comparisons of tissue and urinary radioactivity values between these
groups were expressed in relative terms. However, the calculated values for the total
injected doses of radioactivity in animals that received LAH in vivo were different to
those in animals that did not receive LAH, and so comparisons of tissue and urinary
radioactivity values between these groups were expressed in absolute terms.
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The bladder urinary radioactivity was determined using the following methodology :
i) Total radioactivity (from free and bound125 D/lOOuL urine : net CPM/100pL
urine.
ii) Radioactivity from free 125 I/lOOitL urine : (net CPM of 500|±L subsample of
ethanol pecipitation solution) x 2.4. A correction factor of 2.4 (120CH-500) is used
because the 1200pL final volume ethanol precipitation solution contained lOOpL
urine, and 500pL of the 1200|iL was counted.
iii) Radioactivity from bound 1251/100uL urine : (i - ii).
iv) Bladder urinary radioactivity (radioactivity from bound 1251/ bladder urinary
volume): iii(radioactivity from bound125 1/100pL urine) x bladder urinary volume (pLl
100
v) Total dose injected corrected for free 125 I (CPM bound 125 I) : CPM total
(Figure IB, Appendix 1) - percentage of CPM total that was non-precipitable (Figure
IB, Appendix 1).
vi) Bladder urinary radioactivity as percentage of total dose injected (CPM
bound 1251):
iv (bladder urinary radioactivity) x ioo
v (total dose injected)
All plasma, tissue and urine samples were counted together.
Chromatographic analysis of radiolabeled heparin in urine
HPLC analysis of urine was performed using a liquid chromatograph (System Gold,
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Beckman Instruments Inc., Canada) equipped with a model 126 solvent delivery
system and a manual injector. A TSK G3000 SWXL 30cm x 7.8mm column was used
with a mobile phase of 0.5M Na2S04 and a flow rate of 0.5ml/min; AOD at 205nm
was recorded. Preliminary experiments showed that the chromatographic profiles of
high and low molecular weight particles (most likely calcium carbonate and triple
phosphate crystals) present in rabbit urine were indistinguishable from those of
buffered UFH and LMWH. Ethanol precipitation, heat denaturation and treatment
with trypsin all failed to remove the particulate matter. Therefore, urine containing
bound 1251-heparin was applied to the column and the gamma radioactivity in each
eluate was measured. The radioactivity-time profile of eluted rabbit urine was then
compared with the chromatograms of buffered iodinated UFH and LMWH in rabbit
urine, and heparin molecular weight standards. Rabbit urine was precipitated in
absolute ethanol (1 vol urine : 3 vol 100% ethanol at 4° C for 48 hrs) and the
supernatant was discarded after centrifugation (1600 x g at room temperature for 30
minutes). The residual pellet was resuspended in 0.85M saline, 100pL suspension was
applied to the column and 0.5ml fractions were collected. The gamma radioactivity
emitted from each fraction in 1 minute (CPM) was counted. The presence of heparin
in the suspension and the absence of heparin in the supernatant were confirmed by
Alcian Blue testing. 2pL samples of suspension and supernatant were spotted on to
filter paper (lx Whatman's) and air-dried. The paper was then stained in 0.1% Alcian
Blue (10 ml of [O.lg Alcian Blue/ 10ml dH2 0] + 90 ml glacial acetic acid) for 10
minutes, destained in deionised water and air-dried. Control samples were also applied
155
(2pL UFH [lOmg/ml 0.9% NaCl], LMWH [lOmg/ml 0.9% NaCl], 0.9% NaCl and
rabbit urine). The presence of intense blue stain indicative of heparin was confirmed in
the UFH and LMWH samples, absence of stain from the NaCl and rabbit urine
samples was noted, and the presence or absence of the intense blue stain of heparin
was recorded in the test urine samples. The radioactivity-time profiles of the starting
materials were determined. A sample of iodinated UFH or LMWH in rabbit urine (1
vol 125 I-heparin : 3 vol urine) was precipitated in absolute ethanol (1 vol 125 I-
heparin/urine : 3 vol 100% ethanol at 4° C for 48 hrs, followed by centrifugation at
1600 x g at room temperature for 30 minutes, supernatant discarded) and the pellet
was resuspended in buffer (0.5M Na2S04). 200pL suspension was applied to the
column and the gamma radioactivity emitted from each 0.5ml fraction in 1 minute
(CPM) was measured. The radioactivity-time profiles of the non-metabolised and
excreted iodinated heparins were compared and the approximate molecular weights of
the heparin fractions in the eluates containing peak radioactivity were determined
from the molecular weight - retention time standard curve constructed from molecular
weight standards obtained from the manufacturer (Rhone-Poulenc Sante, Canada).
Anticoagulant assays
Plasma heparin concentrations were measured as anti-factor Xa activity (Teien and
Lie, 1977) using the Stachrom heparin kit which had been adapted for use on the
ACL automated coagulation analyser. The assay is carried out with an excess of AT
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Ill to ensure that any existing deficiency of this protein is compensated for. The test
principle is based on the in vitro inhibition of factor Xa by AT IH-heparin complexes :
AT III + heparin —> [AT Hl-heparin]
[AT El-heparin] + Xa (known excess) —> [AT III-heparin-Xa] + Xa (residual)
Xa (residual) + CBS 31.39 -> pNA
The quantity of paranitroaniline (pNA) released at 405 nm is inversely proportional to
the amount of heparin (UFH or LMWH) present in the plasma. A calibration curve is
constructed from standards prepared by adding UFH or LMWH in vitro to pooled
PPP from healthy rabbits (to a final concentration of 0.8U heparin/ml plasma). Two
controls corresponding to 0.8 and 0.4 U heparin/ml plasma (neat and 1:2 dilution of
the appropriate standard) were assayed with each batch of test samples. 25pi
standards, controls or test plasmas were added to 25pl AT III solution and 450pl
diluted buffer, and incubated for 2 minutes at 37° C. 25pl factor Xa, 25pl
chromogenic substrate CBS 31.39 and 25pi 50% acetic acid were then added in turn.
After each addition, the samples were mixed and incubated at 37° C for 30 seconds,
and finally the AOD at 405nm of the sample read against a blank was recorded.
A 3 point calibration curve was constructed on linear graph paper by plotting the
heparin level for each calibration point (0.8U heparin/ml plasma, 1:2 dilution of [0.8U
heparin/ml plasma] and a sample blank of buffer solution [1 vol 10-fold concentrated
Tris EDTA buffer, pH 8.4 : 10 vol ddH20 ]) against the corresponding AOD value.
157
The heparin levels (U/ml) of the test samples were deduced from the calibration
curve. Assay linearity was observed for UFH levels between 0.0 and 0.8 U/ml and for
LMWH levels between 0.0 and 1.0 U/ml. Pooled rabbit PPP was used to dilute
samples into the range of the standard curve. UFH and LMWH levels less than 0.05
U/ml (which was the detection limit of the assay) had no meaningful significance.
Displacement of heparin bound non-specifically to plasma proteins
The anti-factor Xa activity of each plasma sample was assayed to quantify the amount
of unbound UFH or LMWH present. LAH (2.1|iL of 0.585 mg/ml PBS, clanti-factor
Xa U/mg) was then added to each assay sample to displace anticoagulantly-active
heparin which was bound to plasma proteins other than AT III, and the resultant anti-
factor Xa activity assessed. This concentration of LAH represents addition of LAH in
at least 20-fold molar excess to the estimated molar concentration of UFH or LMWH
in each sample and has been shown previously to be in excess of the amount required
to displace all of the protein-bound heparin (Young et al, 1993a). The observed
increment in anti-factor Xa activity cannot be accounted for by the LAH since it has
minimal anti-factor Xa activity (<1 U/mg). Therefore, the amount of anticoagulantly-
active heparin bound to plasma proteins other than AT III is represented by the
difference in anti-factor Xa activity before and after the addition of LAH.
Heparin recovery
Analysis of recovery was limited in the majority of animals to the first 20 minutes
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(first tertile) after heparin administration because there was no significant recovery of
the lowest dose of UFH after this time, and the half-lives of the doses of UFH and
LMWH under study determined that major changes in recovery occurred within the
first 20 minutes of administration. In animals that received LAH in vivo, absolute
plasma heparin concentrations were also assessed over the 60 minutes following
heparin administration, and were compared with similar values obtained from animals
that received only heparin.
The amount of unbound heparin in each plasma sample was quantified by anti-factor
Xa assay. The assay was repeated in the presence of excess LAH to quantify the
amount of free and plasma protein-bound heparin present, or total heparin. The anti-
factor Xa activity was measured in plasma drawn at 5, 10, 15 and 20 minutes after
heparin administration. Recovery was calculated by measuring the area under the
plasma concentration versus time curve (AUC0-20), using the trapezoidal rule method
(Gillies et al, 1986) where the plasma concentration versus time curve is depicted as a
number of trapezoids by drawing straight lines between each adjacent plasma
concentration value (Figure 11). Although the upper side of the trapezoid is a curve,
as the time interval (width of trapezoid) is small, it can be assumed that the upper side
is a straight line and the error incurred is slight. The area of each trapezoid is
calculated from (Figure 11):
area = (C? + CL) x (t2 - h)
2
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Figure 1 1 : Plasma drug concentration versus time curve
can be divided into a series of trapezoids and the area
under the curve can be calculated by the trapezoidal rule
method.
1 60
The sum of the areas of all the trapezoids yields an estimate of AUC0-20. The amount
of unbound heparin in plasma in the first textile after administration was (AUC0-20
unbound), and the total heparin in plasma in the first tertile after administration was
(AUCo-20 Total). (AUCo-20 unbound) was expressed as a percentage of (AUCo-20 Total). As
(AUCo-20 Total) was the same in control and endotoxaemic animals (for each heparin at
each dose, p >0.1 control v LPS-treated animals : Table 12), a reduction in (AUCo-20
unbound) in endotoxaemic animals compared with control animals represents a reduction
in the absolute amount of unbound heparin in endotoxaemic animals compared with
controls.
AUC(0-20 Total)
Heparin dose (U/ml. min)
(anti-factor Xa U/kg) Control LPS-treated p value
UFH 20 8.38 ± 0.87 8.21 ± 1.11 0.85
50 14.23 ± 0.58 17.61 ± 2.65 0.24
100 42.86 ± 3.40 47.48 ± 6.42 0.52
LMWH 20 6.33 ± 0.87 6.73 ± 0.51 0.70
50 12.87 ± 1.49 13.64 ± 1.14 0.70
100 27.74 ± 5.48 30.15 ± 3.77 0.74
Table 12 : AUC(0.2o Total) in control and LPS-treated animals. Results presented
are the mean ± SEM of 5 experiments.
Heparin recovery and LAH in vivo
To assess the effect of RES blockade on plasma heparin concentrations, the anti-
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factor Xa activity in plasma from control animals at 5, 10, 15 and 20 minutes after a
bolus i.v. injection of 50 anti-factor Xa U/kg of heparin was compared with the anti-
factor Xa activity in plasma at similar times in animals that received LAH in vivo 10
minutes prior to the bolus injection of heparin. In animals that received LAH as well
as heparin, at each time point the anti-factor Xa activity of the excess LAH was
subtracted from the plasma anti-factor Xa activity to give the anti-factor Xa activity
of the heparin. The same comparison was made in animals that had been pretreated
with LPS 2 hours prior to the heparin injection. Similarly, the plasma anti-factor Xa
activity in control and LPS-treated animals that received LAH in vivo 15 minutes after
a bolus i.v. injection of 50 anti-factor Xa U/kg of heparin was measured at various
time points up to 1 hour after heparin administration. Again, at each time point after
LAH administration, the plasma anti-factor Xa activity of heparin was calculated by
subtracting the anti-factor Xa activity of the excess LAH from the plasma anti-factor
Xa activity.
Statistical Analysis
The values are reported as mean ± SEM. Differences were determined with Student's
t-test and were considered statistically significant when p<0.05 (Phillips, 1992b).
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APPENDIX 1
CLEARANCE KINETICS : METHODOLOGY
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Plasma radioactivity from total and free 1251: methodology
For each time point, the amount of radioactivity in plasma from total and free 1251 was
determined. The total amount of radioactivity in plasma was determined by counting
the y radiation emitted in one minute fromlOOpL PPP in 900|iL 0.85M saline, in
duplicate. The amount of radioactivity from free 1251 in plasma was determined after
ethanol precipitation of bound 125 I-heparin. Initial experiments determined that
precipitation of bound 125 I-heparin was maximised by addition of 1 vol excess
unlabelled heparin (lmg heparin/100pL 0.85M saline), 1 vol 0.85M saline and 9 vol
absolute ethanol to 1 vol PPP. For each time point, lOOpL PPP were added to lOOpL
0.85M saline, lOOpL excess unlabelled heparin (lmg heparin/100pL 0.85M saline)
and 900pL 100% ethanol, in duplicate. To determine the amount of free 1251 in the
injected mixture of heparin and radiolabelled tracer, 20pL of 2DS were added to
80pL normal rabbit serum (stock sample), IOOjiL 0.85M saline, 100pL excess
unlabelled heparin (lmg hepairn/lOOpL 0.85M saline) and 900pL absolute ethanol, in
duplicate. All samples (plasma, 2DS, ethanol precipitation) were kept at 4° C for 48
hours. The ethanol precipitation samples were then centrifuged (1600 x g for 30
minutes at room temperature) and 500pL supernatant were added to 500(jL 0.85M
saline. The y radiation emitted in one minute from each plasma sample, the 10pL 2DS
(see below) and each ethanol precipitation supernatant sample was counted in
duplicate (gross CPM) and the mean gross CPM of the duplicate samples was
calculated. The machine background radioactivity was calculated from the mean CPM
of 4 x lml 0.85M saline samples; this value was subtracted from the mean gross
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CPM of each sample, giving the CPM net of machine background radioactivity (net
CPM).
At each time point, the percentage of the total injected dose of radioactivity present in
plasma was calculated using the following methodology (Figures 12A-C). All weights
were recorded using an electronic balance (Oertling, Avery Berkel, Canada).
FIGURE 12A
Each rabbit was assigned a unique identification number and its weight was recorded
(a). The volume of radiolabelled tracer required to give a radioactivity dose of
~20.106 CPM (b) and the volume of stock solution containing the allocated dose of
heparin (c) were recorded. The specific activities of the heparins were determined by
the manufacturers (LMWH-100 anti-Xa U/mg; UFH- 160 anti-Xa U/mg)
Dose Injected
Before injection into the rabbit, the weight of the (heparin + radiolabelled tracer)
mixture (in 5 ml volume syringe with sheathed 23G needle attached) was recorded
(d : Full Syringe). Two drops of the mixture were added to 1ml 0.85 M saline
(giving the two drop sample, or 2DS), and the weight of the (heparin + radiolabelled
tracer) mixture minus 2 drops was recorded (e : Minus 2 drops) which was also the
weight of the injected syringe (e : Wt of Injected Syringe). The weight of the 2
drops (f: Wt of drops) is (d - e). To allow the total injected dose of radioactivity to
be calculated, 10 |iL of the 2DS were added to 1 ml 0.85M saline, in duplicate (lOpL
2DS).
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After injection, the weight of the empty syringe (5 ml volume syringe with sheathed
23G needle attached) was recorded (g) and the weight of (heparin + radiolabeled
tracer) mixture injected (h : Dose Injected) is (e - g).
At each time point, the weight of the 5ml volume syringe containing the whole
blood/citrate sample to a total volume of 1.5ml was recorded (i: Full Syringe of
Blood). The syringe was emptied and reweighed (j : Empty Syringe), and the weight
of the blood/citrate sample (k : Difference) is (i-j).
The volumes used to estimate the amount of free I25I by ethanol precipitation of
bound 125 I were recorded (Ethanol Precipitation) and any sampling problems or
difficulties with the rabbit were noted along with the bladder urinary volume
(Additional Comments).
Figure 12B : Total Clearance
i)Total Dose Injected (cpm total) is the total (free and bound 125 I) amount of
radioactivity injected and is calculated from :
e (weight of dose injected") x (CPM of 10|uL 2DS x 100)
f (weight of 2 drops) 1
As the 2 drops were placed in a 1ml volume, (CPM of lOpL 2DS x 100) gives the
CPM in the 2 drops sample.
ii) CPM/kg is CPM injected per kilogramme rabbit _ i (total dose injected)
a (weight of rabbit)
iii) CPM/ml bid is CPM injected perml blood _ ji *
58
* assuming 58ml blood vol/kg (Canadian Council on Animal Care, 1993a).
iv) CPM/ml plasma is CPM (bound and free 1251) injected per ml plasma _ iii
0.58
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assuming a haematocrit of 0.42 (Canadian Council on Animal Care, 1993a), and no
radioactivity bound to red blood cells (Young and Hirsh, 1990).
v) Weight of blood + 0.2ml citrate : k.
vi) Weight of blood : (v - 0.2).
vii) Weight of plasma : (vi x 0.58), assuming a haematocrit of 0.42 (Canadian
Council on Animal Care, 1993a).
viii) Weight of plasma + 0.2 ml citrate : (vii + 0.2).
ix) CPM/ml plasma + citrate : (net CPM of each sample x 10), as the radioactivity
in lOOpL volumes of plasma and citrate was counted.
x) CPM/ml plasma:
viii (weight of plasma + 0.2 ml citrate) x ix (CPM/ml plasma +citrate)
vii (weight of plasma)
xi) % of total dose: x (cpm/ml plasma! x 100
iv (total cpm/ml plasma)
Figure 12C : Corrected Clearance
Total radioactivity (from bound and free 1251) corrected for free 125 I using ethanol
precipitation data.
xii) CPM/ml plasma + citrate is the CPM from free1251 per ml plasma + citrate and
is calculated from radioactivity values of ethanol precipitation supernatant samples :
net CPM from free 1251 x 1200 x 10 *
500
* Correction factor of x 24 ([1200-^500]x10) is used because i) net CPM from free125I
is the radioactivity from free1251 in 500|jL of 1200pL ethanol precipitation mixture,
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and ii) lOOpL of plasma was added to ethanol precipitation mixture.
xiii) CPM/ml plasma is CPM from free1251 perml plasma :
viii ("weight of plasma + 0.2 ml citrate! x xii (CPM/ml plasma + citrate)
vii (weight of plasma)
xiv) Corrected CPM/ml plasma is the radioactivity from heparin-bound 1251 per ml
plasma : x (CPM [bound and free1251]/ml plasma) - xiii (CPM [free 1251]/ml plasma)
xv) % Non-Precipitable is the percentage of total 125I that is free, or non-
precipitable, per ml plasma :
xiii fCPM from free 125 I/ml plasma) x 100
x (CPM from bound and free 125 I/ml plasma)
xvi) Corrected % is the amount of bound 125I per ml plasma expressed as a
percentage of iv CPM (bound and free 125I) injected per ml plasma corrected for
free125I in the following way :
1. iv CPM (bound and free 1251) injected/ml plasma corrected for free 1251:
a) CPM from free1251 in 20|iL 2DS is calculated from net CPM 20pL 2DS :
net CPM 20(iL 2DS x 1200 *
500
* Correction factor of x 2.4 is required because 20pL of 2DS were added to ethanol
precipitation solution of final volume 1200|iL and (net CPM 20pL 2DS) is the
radioactivity in 500pL of the 1200jjL volume.
b) CPM (from bound and free 1251) in 20pL 2DS : (net CPM lOpL 2DS x 2 ).
c) Percentage of total dose injected that is free 1251 (let this be x):
a) CPM from free 1251 in 20pL 2DS * x 100
b) CPM from bound and free 1251 in 20pL 2DS *
* as 20pL 2DS is representative of 2DS and so total injected dose.
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d) CPM (free1251) injected/ml plasma :
iv CPM (bound and free1251) injected/ml plasma x x
100
e) Corrected CPM (bound 125I) injected/ml plasma :
iv CPM(bound and free125I) injected/ml plasma - d) CPM(free1251) injected/ml plasma
2. At each time point, amount of bound 1251 per ml plasma expressed as a percentage
of the corrected CPM (bound 1251) injected perml plasma = xvi:
xiv (CPM bound 1251 / ml plasma! x 100







d Full Syringe 5.8489
eMinus 2 drops_
fWt of drops 0.0228
b
Volume of tracer 125p,L « 21.10 6 CPM
Volume of heparin 1.5ml (0.94mg) of
12.5mg UFH in 20ml N saline
—» ~ 50anti-Xa U/kg
(g)
eWt of Injected Syringe 5.8261





of Blood j Empty Syringe
kDifference
1 min 5.1143 3.6174 1.4969
2 min 5.0608 3.5929 1.4679
3 min 5.0774 3.6045 1.4729
4 min 5.1014 3.6201 1.4813
5 min 5.0337 3.5431 1.4906
10 m n 5.1168 3.6184 1.4984
15 m n 5.0488 3.5394 1.5094
20 m n 5.0408 3.5339 1.5069
25 m n 5.0245 3.5222 1.5023
30 m n 5.0422 3.5814 1.4608
40 m n 5.0501 3.5309 1.5192
50 in n 5.0258 3.5082 1.5176
60 m n 5.0343 3.5308 1.5305
Ethanol Precipitation Vol of plasma lOOuL + lOOpL UFH (1 mg UFH/
100pL 0.85M saline)
Vol of 0.85 M NaCl IQOuU
Vol of absolute ethanol 900|il,
Additional Comments Bladder urinary volume : 15ml.
170





















































































































































































































For each animal, the percentage of the injected dose of radioactivity present in 1ml
plasma (% corrected) was plotted against time after transformation of radioactivity
into logarithmic values. The curvilinear profile of the semilogarithmic plasma
concentration versus time curve suggested a 2-compartment model where the
biexponential curve can be described by 2 exponential terms; the slope of the residual
line is - a where a is the distribution rate constant of the drug, while the terminal
slope from the post-distributive phase of the curve is -p where (3 is the terminal
elimination rate constant of the drug. The distribution and elimination half-lives (ti/2 a
and ti/2 P) were determined by linear regression analysis. The slope of the regression
line representing the distribution phase is -a and ti/2 a = 0.693/a; the slope of the
regression line representing the elimination phase is -P and tJ/2 P = 0.693/p, according
to the following (Gillies et al, 1986):
all straight lines can be defined by :
Y = mX + b
where : m = the slope of the line and b = intercept of the Y axis.
For semilogarithmic plasma drug concentration versus time plots :
Y = In (natural log) of drug concentration in plasma
X = time after dose
m = slope of line
b = intercept on In plasma drug concentration axis
giving:
In drug concentration = (slope x time) + In concentration at Y intercept
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Where drug elimination is first-order :
slope = - elimination rate constant
or : - slope = elimination rate constant
Therefore, Y = mX + b becomes :
In drug concentration = (- elimination rate x time) + In y-intercept
Let:
In C = In of drug concentration
K = elimination rate constant
t = time after dose
In C0 = In of drug concentration at intercept of y axis
giving:
In C = In Co - Kt
By definition of half-life (ti/2), the concentration (C) at the time (t) equal to the half-
life is one-half of the original concentration (C0). Therefore, at one tm , the
concentration is one-half of what it was at the start, or at t = ti/2 , C = 1/2 C0 .
Assuming C0 = 1, then :
In 0.5 Co = In Co - K(t1/2)
-> In 0.5 = In 1 - K(t,/2)
Transforming this equation algebraically gives :
K(ti/2 ) = In 1 - In 1/2





As a and (3 are similar to K in that they represent the distribution and terminal
elimination rate constants, respectively, it follows that:
11/2 = 0.693 and ti/2 = 0.693
a 3
where:
a: negative slope of the residual line
3 : negative slope of the line from the post-distributive phase of the curve
and slope of the line is :
In C2 - In Ct
t2 - ti
where:
C2 : second concentration
Ci : first concentration
t2 : time corresponding to C2





Weight of Organs in 2.5kg male New Zealand White rabbit
Total








Liver3 33.8083 14.4710 19.3373
33.5180 14.1506 19.3674
33.5012 14.2165 19.2847 73.1399
28.8123 13.6618 15.1505
Spleen 14.3454 13.5478 0.7976 0.7976
R kidney 20.6102 13.3535 7.2567
14.72314
L kidney 20.9163 13.4499 7.4664
1
Organs from 2.5 kg rabbit used for assessment of in vivo anticoagulant activity of
excess LAH were removed intact at post mortem, blotted to dryness and placed in
polypropylene containers prior to weighing on electronic scales.
2 The weight of the container and tissue was recorded, the tissue was removed, and
the empty container was weighed. The weight of the tissue is the difference in weights
between the full and empty container.
3 The liver had to be divided into 4 pieces to facilitate removal as it was impractical to
remove it whole.
4 The weights of the right (R) and left (L) kidneys were added to give the weight of





The variable anticoagulant response to
unfractionated heparin in vivo reflects binding to
plasma proteins rather than clearance
LYNN MANSON, JEFFREY I. WEITZ, THOMAS J. PODOR, JACK HIRSH and EDWARD YOUNG
HAMILTON, ONTARIO, CANADA
The anticoagulant response to fixed doses of unfractionated heparin is variable in
patients with acute illness, and some patients with venous thromboembolism re¬
quire high doses of heparin to achieve a therapeutic anticoagulant response. To
investigate the mechanism responsible for the variable anticoagulant response to
heparin in acute illness, heparin clearance and nonspecific protein binding were
compared in control and endotoxin-treated rabbits. The plasma half-life (t1/2) of
radiolabeled heparin increased in a dose-dependent fashion. At all doses of hep¬
arin studied, the t)/2 of radiolabeled heparin was unaffected by experimental
endotoxemia when compared with control animals. In contrast, the amount of
heparin recovered was lower in the plasma of endotoxemic animals because of
increased binding to plasma proteins. A chemically modified heparin with low
affinity for antithrombin III was added ex vivo or in vivo to displace heparin bound
nonspecifically to plasma proteins. The proportion of heparin bound to plasma
proteins was significantly greater in the plasma of endotoxemic animals than in
controls. These findings indicate that acute inflammation alters heparin recovery but
does not affect heparin clearance. The variability of the anticoagulant response to
heparin seen in patients with thromboembolism may, in part, be due to this effect of
the underlying disease process. (J Lab Clin Med 1997;130:649-55)
Abbreviations: AUC = area under the curve; LAH = low-affinity heparin; LPS = lipopolysac-
charide; t1/2 = plasma half-life; SHPP = 3-(4-hydroxyphenyl) propionic acid N-hydroxysuccin-
imide ester
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Heparin is an effective anticoagulant in a va¬riety of thrombotic disorders.1 The use ofheparin can be complicated by marked vari¬
ability in the dose response among patients with
thrombosis.2 In addition, some patients with acute
thrombosis require very high doses of heparin to
obtain an adequate response.3
The anticoagulant effect of heparin is mediated
through its specific binding to antithrombin III.4"6
Heparin also binds nonspecifically to a number of
plasma proteins such as platelet factor-4, histidine-
rich glycoprotein, vitronectin, fibronectin, and von
Willebrand factor.7 There is evidence that these
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nonspecific interactions can reversibly neutralize the
anticoagulant effect of heparin by limiting the
amount of heparin available to bind to antithrombin
III.8'9 Some of the heparin-binding proteins are
acute phase reaction proteins, the levels of which
increase to a variable extent during illness.10"12
There are two potential explanations for the
marked variability of the anticoagulant response to
heparin. First, nonspecific binding of heparin to
plasma proteins8'9 or to platelet factor-41314 or high-
molecular-weight von Willebrand factor,15 which
are released from activated platelets or endothelial
cells, may reduce the amount of heparin available to
catalyze antithrombin III. In previous studies, we
showed that nonspecific binding of unfractionated
heparin to plasma proteins markedly impairs its an¬
ticoagulant activity in patients with venous throm¬
boembolism.16 A second possibility is that alter¬
ations in heparin clearance may be involved. It is
generally accepted that unfractionated heparin is
cleared from the blood by a combination of a satu¬
rable mechanism and a nonsaturable mecha¬
nism.17'18 The saturable mechanism is thought to
reflect heparin binding to vascular endothelial cells
and reticuloendothelial cells. In support of these
concepts, cultured endothelial cells have specific
heparin binding sites on their surface,19'2() and these
cells as well as macrophages have been shown to
internalize and degrade heparin.21"23 At low doses,
heparin is cleared mainly by the highly efficient
saturable mechanism. At higher doses, the cellular
binding sites are saturated, and heparin is cleared
predominantly by renal elimination.17'18 Thus any
alterations in heparin clearance caused by increased
binding to endothelial cells or blockade of the re¬
ticuloendothelial system may explain the reduced
heparin recovery in acutely ill patients.
The purpose of this study was to examine the
mechanism responsible for reduced heparin recov¬
ery in disease states. To accomplish this, we used
endotoxin infusion to induce acute illness in rabbits
and examined the relative roles of reversible, non¬
specific protein binding and heparin clearance as
determinants of heparin recovery.
METHODS
Reagents. Unfractionated heparin (160 anti-factor Xa
U/mg) was obtained from Rhone-Poulenc Rorer, Mon¬
treal, Canada, or from Sigma Chemical Co., St. Louis, Mo.
(157 anti-factor Xa U/mg). SHPP was supplied by Pierce,
Brockville, Canada. Carrier-free iodine 125 was obtained
from Dupont, Wilmington, Del. Purified bacterial LPS
obtained from Salmonella minnesota R595 (Sigma Chem¬
ical Co.) was suspended in sterile phosphate-buffered sa-
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line solution at a concentration of 2 mg/ml and was solu-
bilized by sonication.
Preparation of ,25l-labeled heparin Unfractionated
heparin was reacted with SHPP and labeled with 125I
according to the method of Dawes and Pepper.24 When
compared with the unlabeled starting material, the mo¬
lecular weight distribution (as determined by high-perfor¬
mance liquid chromatography)9 and biologic activity (as
measured by anti-factor Xa assay) of the 125I-labeled hep¬
arin were unchanged.
Preparation of LAH. LAH was prepared from unfrac¬
tionated heparin by controlled periodate oxidation and
borohydride reduction according to the method of Casu et
al.25 with minor modifications26 to remove residual high-
affinity material. The anti-factor Xa activity of the LAH
was <1.0 U/mg.
Heparin recovery and clearance in healthy and LPS-
treated rabbits. All animal studies were carried out in
accordance with the recommendations of the Canadian
Council of Animal Care and were approved by the Animal
Research Ethics Board of McMaster University.
Specific pathogen-free New Zealand White male rab¬
bits (Charles River Laboratories, St. Constant, Canada),
ranging in weight from 2.5 to 3.0 kg were given a 1.5 ml
bolus of either LPS (10 p.g/kg diluted in 0.9% NaCl) or an
equivalent volume of saline solution into the marginal ear
vein. Two hours later the rabbits received a 1.5 ml bolus of
either 20, 50, or 100 anti-factor Xa U/kg of heparin to
which a tracer amount (10 pcCi, <1 anti-factor Xa U) of
125I-labeled heparin had been added. The heparin doses
chosen span the doses used clinically. In addition, these
doses have been shown to have been cleared predomi¬
nantly by the saturable mechanism of heparin clearance.18
The total radioactivity administered was determined in a
gamma counter (model 1272; LKB-Pharmacia, Fisher Sci¬
entific, Toronto, Canada) before injection. In some exper¬
iments, LPS-treated or control rabbits were given a bolus
of LAH (6.25 mg/kg, 20-fold molar excess) either 10 min¬
utes before or 15 minutes after receiving 50 anti-factor Xa
U/kg of heparin. LAH was used to displace anticoagu-
lantly active heparin from plasma proteins other than
antithrombin III, to displace heparin bound to endothelial
cells, and to block uptake by the reticuloendothelial cells.
To study the effect of LAH alone, two control rabbits
were given only a bolus of LAH.
Preparation of platelet-poor plasma. Blood samples
(1.3 ml into 200 pel of 3.8% sodium citrate) were taken
from the contralateral central ear artery immediately be¬
fore and at 5-minute intervals after heparin administra¬
tion. The blood lost was replaced with normal saline
solution. The experiments were terminated at the end of 1
hour and the rabbits were killed. Each blood sample was
carefully weighed to determine the mass of blood col¬
lected. After centrifugation at 1600 g at room temperature
for 15 minutes, platelet-poor plasma was harvested.
Heparin recovery based on anticoagulant activity. To
monitor heparin recovery, the anti-factor Xa activity of
heparin in each plasma sample was determined by using
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20 5.0 ± 0.6 o+lco 3.4 ± 0.7 39.6 ± 4.5*
50 9.5 ± 0.6 14.2 ± 0.6 4.8 ± 0.4 33.7 ± 2.7f
100 32.9 ± 1.9 42.9 ± 3.4 10.0 ± 2.3 22.4 ± 3.7f
LPS-treated
20 3.5 ± 0.7 8.1 ± 1.1 4.6 ± 0.7 56.8 ± 6.7*
50 10.0 ± 1.5 17.6 ± 2.7 7.6 ± 1.2 43.4 ± 1,8f
100 28.9 ± 2.1 47.5 ± 6.4 18.4 ± 4.7 37.2 ± 5.5f
Values are expressed as mean ± SEM for 4 or 5 animals per group. The amount of heparin recovered was determined as anti-factor Xa activity and was calculated
from the AUC for the first 20 minutes after administration of heparin (column 1). Excess L4H was added ex vivo to displace heparin from plasma protein-binding
sites, and the AUC again was calculated (column 2). The difference between column 1 and column 2 is the amount bound to plasma proteins (column 3) and is
used to determine the percentage of heparin bound to plasma proteins (column 4).
*p = 0.8.
tp < 0.05.
the method of Teien and Lie.27 The Strachrom heparin kit
from Diagnostica Stago (Wellmark Diagnostics, Guelph,
Canada) was adapted for use on the ACL automated
coagulation analyzer (Instrumentation Laboratory, To¬
ronto, Canada). Aliquots of pooled platelet-poor plasma
from healthy rabbits to which known amounts of heparin
were added were used as standards.
To assess the amount of heparin that is bound nonspe-
cifically to plasma proteins (reversible heparin binding) ex
vivo, the anti-factor Xa activity was measured before and
after the addition of 90 |xg/ml of LAH. This concentration
of LAH was chosen because previous studies demon¬
strated that it exceeds the amount of LAH needed to
totally displace the protein-bound heparin.8 The anti-fac¬
tor Xa activity measured before LAH addition reflects the
amount of heparin that is not bound to plasma proteins.
By subtracting this value from the anti-factor Xa activity
measured after LAH addition, the amount of heparin
bound to plasma proteins can be calculated.
Recovery of heparin in the first 20 minutes after hepa¬
rin injection was calculated by plotting the heparin con¬
centration as a function of time and measuring the AUC
by using the trapezoidal rule method.28 We restricted
analysis to the first 20 minutes after heparin administra¬
tion, because at the heparin doses tested, most of the
anti-factor Xa activity was cleared during this time inter¬
val.
Clearance of 125l-labeled heparin. To determine hep¬
arin clearance, two 100 pi aliquots of plasma samples
from each time point were each mixed with 300 pi of
absolute alcohol to precipitate heparin and plasma pro¬
teins. After incubation overnight at 4° C, the samples were
centrifugated at 4000 g for 15 minutes at room tempera¬
ture, and the amount of 125I-labeled heparin in the pre¬
cipitate was determined in a gamma counter. The disap¬
pearance of labeled heparin as a function of time was then
plotted, and the t1/2 was determined by linear regression
analysis after logarithmic transformation. The slope of the
regression line, which represents the elimination phase, is
designated -(3, and the t1/2 is 0.693/p.28
Statistical analysis. The values are reported as mean ±
SEM. All data were analyzed by using Student's t test, and
differences were considered significant at a value of p <
0.05.
RESULTS
Recovery of heparin ex vivo. Anti-factor Xa activity
in each plasma sample was assayed before and after
the addition of 90 p.g/ml of LAH. Because LAH
displaces anticoagulantly active heparin from
plasma proteins, the anti-factor Xa activity after
LAH addition represents the total amount of hep¬
arin recovered. This was determined from the AUC
for the first 20 minutes after heparin administration.
The amount of heparin that bound nonspecifically
to plasma proteins was calculated by subtracting the
amount recovered before LAH addition from that
measured after LAH addition. As shown in Table I,
the amount of heparin bound to plasma proteins is
markedly higher in the LPS-treated group than in
controls for each dose of heparin administered.
Thus the percentage of heparin bound nonspecifi¬
cally to plasma proteins is significantly higher (ap¬
proximately 1.5-fold, p < 0.05) in the LPS-treated
animals who received 50 and 100 anti-factor Xa
U/kg when they are compared with controls, and the
result is close to significance (p = 0.08) in the group
that received 20 anti-factor Xa U/kg.
Comparison of unfractionated heparin recovery ex
vivo and in vivo. To compare the amount of heparin
that could be recovered when LAH is added ex vivo
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Table II. Amount of heparin recovered when LAH
is added ex vivo or is administered in vivo
Amount recovered after LAH
(fx min)
ml
LAH added LAH administered
ex vivo* in vivot
Control 14.2 ± 0.6 15.5 ± 0.7
LPS-treated 17.6 ± 2.7 18.2 ± 1.4
All rabbits received 50 anti-Xa U/kg of heparin. The amount of heparin
recovered was determined as anti-factor Xa activity and was calculated
from the AUC for the first 20 minutes after administration of heparin. Values
are expressed as mean ± SEM for 4 or 5 animals/group. There are no
significant differences between the groups (p > 0.1).
"Excess LAH was added to each sample ex vivo.
fExcess LAH was administered in vivo 10 minutes before injection of hep¬
arin.
(see above) with the recovery of heparin when LAH
is given in vivo, excess LAH (6.25 mg/kg) was ad¬
ministered 10 minutes before the injection of hepa¬
rin (50 anti-factor Xa U/kg). As a control, some
rabbits were given LAH alone, and the small
amount of anti-factor Xa activity, when measured in
the plasma of these rabbits, was subtracted from the
anti-factor Xa activity measured in the plasma of
rabbits that received heparin after being given LAH.
The amount of heparin recovered was then deter¬
mined in terms of anti-factor Xa activity and ex¬
pressed as the AUC for the first 20 minutes after
heparin injection.
As shown in Table II, there is no significant dif¬
ference between the total amount of heparin that
can be recovered when LAH is added ex vivo or
when LAH is injected in vivo. Furthermore, there is
no significant difference in heparin recovery be¬
tween the LPS-treated and the control animals.
These results show that LAH is able to displace
heparin from protein binding sites in vivo and that
the extent of reversible heparin neutralization that
occurs in vivo can be assessed reliably ex vivo by
adding LAH.
Clearance of ,25l-labeled heparin. Tracer amounts of
125I-labeled heparin were added to various doses of
unlabeled heparin and injected into control or LPS-
treated animals. The t1/2 values were calculated from
the radioactivity in the plasma samples and are
shown in Table III. The elimination of 12;T-labeled
heparin was dose-dependent and increased as the
dose of unlabeled heparin increased. Thus the t1/2
after administration of 100 anti-factor Xa U/kg was
2.2 times longer than after 20 anti-factor Xa U/kg
and was 1.7 times longer than after 50 anti-factor Xa
U/kg. However, there is no significant difference in
the t1/2 of 12H-labeled heparin in LPS-treated rab-
J Lab Clin Med
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Table III. Plasma t1/2 values of 125l-labeled heparin
in control and LPS-treated animals after




Control LPS-treated p value
20 10.0 ± 1.0 11.9 ± 1.1 0.28
50 13.6 ± 1.2 16.8 ± 0.9 0.07
100 22.5 ± 0.7 23.6 ± 1.9 0.60
Plasma t1/2 values were determined by linear regression analysis of the
semilogarithmic plot of plasma radioactivity versus time. The slope of the
regression line representing the elimination phase is -0, and the t1/2 is
0.693/0. Values are expressed as mean ± SEM for 4 or 5 animals/group.
bits when compared with that in controls at each
dose of unlabeled heparin administered.
Clearance of radioactivity and anti-factor Xa activity
after LAH in vivo. Further experiments were performed
to determine whether LAH administration in vivo
displaced heparin bound to endothelial cells in ad¬
dition to displacing heparin bound to plasma pro¬
teins. To achieve this aim, heparin (50 anti-factor
Xa U/kg) and tracer amounts of radiolabeled hep¬
arin were given to a group of LPS-treated rabbits,
and this was followed 15 minutes later by LAH (6.25
mg/kg). If heparin was also bound to vascular endo¬
thelial cells, the addition of LAH would be expected
to increase both the anti-factor Xa activity (because
of heparin bound to plasma proteins) and radioac¬
tivity (because of heparin bound to vascular endo¬
thelium).
As shown in Fig. 1, when LAH was administered
15 minutes after heparin, there was an almost 50%
increase in anti-factor Xa activity (from 0.39 ± 0.03
U/ml immediately before LAH administration to
0.58 ± 0.06 U/ml 5 minutes after LAH administra¬
tion; p < 0.02). In contrast, there was no significant
increase in the amount of radiolabeled heparin re¬
covered in the plasma (i.e., 28.0% ± 4.5% of the
total radiolabeled dose injected was present imme¬
diately before LAH administration and 26.4% ±
3.6% of the total radiolabeled dose injected was
present 5 minutes later; p > 0.05). These findings
indicate that at the dose of heparin studied, the
increase in anticoagulant activity in plasma after
administration of LAH in vivo is the result of dis¬
placement of heparin from circulating heparin-bind-
ing proteins and is not caused by displacement of
heparin from endothelial binding sites. There was,
however, a change in the slope of the radioactivity
clearance curve after LAH administration. Because
the clearance of unfractionated heparin is dose de¬
pendent (Table III),17,18 this change in slope likely
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Fig. 1. Effect of LAH administered in vivo on the clearance of plasma heparin concentration and
radioactivity in LPS-treated rabbits. Heparin (50 anti-factor Xa U/kg) mixed with tracer amounts of
radiolabeled heparin was administered first, followed 15 minutes later by the injection of LAH (6.25
mg/kg) to displace heparin from protein-binding sites. Plasma heparin concentrations (measured as
anti-factor Xa activity) and radioactivity were measured as described in Methods. LPS was administered
2 hours before the heparin. Values are expressed as mean ± SEM for 4 animals.
reflects the increase in heparin concentration
caused by LAH administration.
DISCUSSION
The relative contributions of nonspecific plasma
protein binding and altered clearance to the vari¬
ability in dose response to heparin and to the im¬
paired anticoagulant response observed in some pa¬
tients with acute venous thromboembolism are
uncertain. Our group has reported that heparin
binding to plasma proteins is an important determi¬
nant of the heparin dose required to produce a
therapeutic heparin level.16 The results of our study
suggested that increased levels of heparin-binding
proteins contribute to heparin resistance observed
among patients with venous thromboembolism but
that other mechanisms may also play a role in the
reduced heparin recovery observed in patients with
high heparin requirements.29
In this study we examined the effect of acute
inflammation on heparin clearance and reversible
protein binding. We used an established experimen¬
tal model (endotoxin administration) to induce
acute illness in rabbits. This model has been shown
to increase the level of heparin-binding proteins in
rat plasma3" and to potentiate the development of
venous thrombosis in rabbits.31
Our results show that the amount of heparin that
is bound nonspecifically to plasma proteins is mark¬
edly elevated in the plasma of LPS-treated rabbits
(Table I). This is similar to the increase observed in
LPS-treated rats.30 We attribute these findings to an
increase in the plasma levels of heparin-binding pro¬
teins. Moreover, our results show that the increase
in protein binding, which was previously demon¬
strated by the addition of LAH in vitro8'16 or ex
vivo
II).
16,32 can also be demonstrated in vivo (Table
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We used a dose of endotoxin that produced major
multisystem perturbations within 2 hours of admin¬
istration.33 Because hepatic acute-phase protein
mRNA does not increase significantly for 4 to 8
hours after acute phase induction, and because the
release of newly synthesized acute phase proteins
occurs many hours after the onset of inflamma¬
tion,34"36 it is likely that the model of acute inflam¬
mation used in our studies predominantly assessed
the extent of reversible heparin binding to proteins
that are released from storage sites in endothelial
and other vascular cells as a response to endotoxin
injury. Thus heparin-binding proteins such as plate¬
let-factor 4,13'14 lactoferrin,37 and high-molecular-
weight multimers of von Willebrand factor13 may be
released from endotoxin-activated platelets, neutro¬
phils, and endothelial cells, respectively. A similar
situation may occur in human patients, because pa¬
tients with thrombotic disorders can show a reduced
anticoagulant response to heparin within a few
hours of onset of their symptoms.
Our results demonstrate that reversible heparin
binding is an important mechanism for the reduced
heparin recovery in acute illness. In contrast, we
found no evidence of increased heparin clearance.
Thus the circulating t1/2 of heparin in endotoxemic
rabbits was not different from that in controls, even
though heparin recovery was markedly reduced (Ta¬
ble III). Our finding that endotoxemia does not
increase heparin clearance is similar to the previous
observation that acute venous thrombosis does not
reduce heparin t1/2.2 In contrast, heparin clearance
has been reported to be increased in clinical and
experimental pulmonary emboli.3'3 This difference
may be due to the nature of the thrombi found in
venous thrombosis and in pulmonary embolism.
When LAH was given after heparin, it produced a
marked increase in anticoagulant activity by displac¬
ing heparin from plasma proteins. In contrast, there
was no change in the radioactivity clearance curve
(Fig. 1). There are two potential explanations for
these findings. First, it is possible that when given in
clinical doses (i.e., 50 anti-factor Xa U/kg) heparin
does not exhibit reversible binding to vascular en¬
dothelial cells or macrophages in the reticuloendo¬
thelial system. A second possibility is that heparin is
rapidly internalized by these cells and thus inacces¬
sible to displacement by LAH. This is supported by
studies demonstrating that endothelial cells and
macrophages can internalize and degrade hepa-
20-23 39
rin. '
In summary, using an animal model of acute en¬
dotoxemia, we have demonstrated that the phenom¬
enon of impaired heparin recovery is caused by an
increase in the concentration of heparin-binding
proteins. This observation has important clinical im¬
plications, because nonspecific binding of heparin to
plasma proteins decreases its anticoagulant effect by
limiting the amount available to bind to antithrom-
bin III. We found no evidence that increased hepa¬
rin clearance contributes to the reduced heparin
recovery observed in acute illness. Although the
results in rabbits may be quantitatively different
from those in human patients, they are likely to be
qualitatively similar. Our studies suggest that the
variable anticoagulant response to heparin seen in
patients with venous thrombosis is likely to reflect
plasma protein binding rather than alterations in
heparin clearance.
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